{"count":100,"events":[{"actor":{"id":"reviewer:will-blair-bot","type":"human"},"after_hash":"sha256:93660ab7accf1fef0bab7a95875f77f8cc30bb1de28de9034c53f62a0bd739c1","before_hash":"sha256:null","caveats":["Manual findings require evidence review before scientific use."],"id":"vev_00bd89051d105094","kind":"finding.asserted","payload":{"proposal_id":"vpr_0c933959d5dd71ab"},"reason":"Manual finding added to frontier state","schema":"vela.event.v0.1","signature":"3d2ec094bf081fa593dd9424301051f909f82e17823f90c617fdd13b49f229e5d42062466a5790cf7adf01d13ad6061b2f1f67925a022dfae838dd96d4f0920b","target":{"id":"vf_98bca71097f11704","type":"finding"},"timestamp":"2026-05-06T03:57:47.492165+00:00"},{"actor":{"id":"reviewer:will-blair-bot","type":"human"},"after_hash":"sha256:8d19fbbcea22a7138ba17ef5ec4780c29fdba6dab46d716f8d23596c0dd2e24d","before_hash":"sha256:null","caveats":["Manual findings require evidence review before scientific use."],"id":"vev_0163b06166e0968f","kind":"finding.asserted","payload":{"proposal_id":"vpr_b5c3e00a41384900"},"reason":"Manual finding added to frontier state","schema":"vela.event.v0.1","signature":"865b6f39ce6caffe3bb8ee8496027c0d2b1bc7d09808404462ea0c407844c143f6a7a1138fbbf57e82fc8a4c17fef09b21b55c6dbf8a4809bbea56b7ab522f00","target":{"id":"vf_ceb7add1b9699180","type":"finding"},"timestamp":"2026-05-06T03:57:51.128247+00:00"},{"actor":{"id":"reviewer:will-blair-bot","type":"human"},"after_hash":"sha256:135e5d7c1ea0a0bbe257e29e647eb7f9f67655d37826dd3448819a487fd43578","before_hash":"sha256:8a2f579ca3888aa7f2af85291b8ca109a599e3484af01df5b5691655c53c355a","caveats":[],"id":"vev_01881399ca4a6a01","kind":"finding.confidence_revised","payload":{"affected":0,"cascade_fired":false,"new_score":0.58,"previous_score":0.61,"proposal_id":"vpr_816a9046d43fd5e2"},"reason":"Decision-critical threshold deserves high review priority but is not itself a therapeutic effect.","schema":"vela.event.v0.1","signature":"1f36e9bea901d1b761844dda9fd7a00a728b7de63d3fa473bc6e3d714ed830d11ae7f32dfbff86308dad29c8992aef9c827c446b8944c1fc02c67220a5bec307","target":{"id":"vf_29671540d388fc5d","type":"finding"},"timestamp":"2026-05-06T03:57:54.388304+00:00"},{"actor":{"id":"agent:vela-curation-bot-2026-05-09","type":"human"},"after_hash":"sha256:d78bb9a307307ee58bf3ada0f9db1ffad9756f28a55a406d0c826a43eff8a88f","before_hash":"sha256:2f33fdd2756ad285a48264b916362445250238a73d231c0e963dc6f3443f8476","caveats":[],"id":"vev_02998164eba87654","kind":"finding.reviewed","payload":{"proposal_id":"vpr_02cc6836a2d1d57f","status":"accepted"},"reason":"Verubecestat EPOCH (Egan et al., NEJM 2018) and APECS were halted for futility, establishing BACE1 inhibition as a failed translation arm. The failed-trial finding is well-supported. Agent-drafted accept; eligible for human re-review.","schema":"vela.event.v0.1","target":{"id":"vf_3d380bcccbe5850e","type":"finding"},"timestamp":"2026-05-09T21:33:46.546819+00:00"},{"actor":{"id":"reviewer:will-blair-bot","type":"human"},"after_hash":"sha256:431ca2b194ba20f6ff47de68363d3a14a2dd835042e10a7bdf121d9889c824dd","before_hash":"sha256:null","caveats":["Manual findings require evidence review before scientific use."],"id":"vev_02a59963890df023","kind":"finding.asserted","payload":{"proposal_id":"vpr_b647f9eb3df29808"},"reason":"Manual finding added to frontier state","schema":"vela.event.v0.1","signature":"a3901663f80b8870350def63648907030800e12cb06ed5280d29d833fbcb400e29a05293ea7b17789454b860369299372f06097f74f3fe64a11fb7ceea606200","target":{"id":"vf_0973a3c4a839b774","type":"finding"},"timestamp":"2026-05-06T03:57:49.348392+00:00"},{"actor":{"id":"reviewer:will-blair-bot","type":"human"},"after_hash":"sha256:null","before_hash":"sha256:null","caveats":[],"id":"vev_02e6be4f4d5bdfa1","kind":"artifact.asserted","payload":{"artifact":{"access_tier":"public","content_hash":"sha256:aec663d20416d9ef8ee3a66013eaf8b72e1b21f0c8d4a528b34f7f2b74f9e21f","created":"2026-05-06T07:21:05.567336+00:00","id":"va_247e88fad116c204","kind":"code","license":"repository code; Vela project source","locator":".vela/artifact-blobs/sha256/aec663d20416d9ef8ee3a66013eaf8b72e1b21f0c8d4a528b34f7f2b74f9e21f","media_type":"text/x-python","metadata":{"code_role":"ingest_catalog_validator"},"name":"Anti-amyloid ingest catalog validator","provenance":{"authors":[],"citation_count":null,"doi":null,"extraction":{"extracted_at":"2026-05-06T07:21:05.567321+00:00","extractor_version":"0.54.0","method":"artifact_deposit","model":null,"model_version":null},"journal":null,"license":"repository code; Vela project source","openalex_id":null,"pmc":null,"pmid":null,"review":null,"source_type":"database_record","title":"Anti-amyloid ingest catalog validator","url":"https://github.com/vela-science/vela/tree/main/scripts/check-anti-amyloid-ingest-catalog.py","year":null},"retracted":false,"size_bytes":11021,"source_url":"https://github.com/vela-science/vela/tree/main/scripts/check-anti-amyloid-ingest-catalog.py","storage_mode":"local_blob","target_findings":["vf_45b4e018839586ea"]},"proposal_id":"vpr_6aa0d6e82a7071e6"},"reason":"code artifact deposit","schema":"vela.event.v0.1","signature":"358e2082518fd810a502e39e960bbd82f41912dd7b76a1a4b532d376de529dcc27b9975d7102aa892524523180e61c04333521e05bf5701c8d0a92899cc9a402","target":{"id":"va_247e88fad116c204","type":"artifact"},"timestamp":"2026-05-06T07:21:05.579920+00:00"},{"actor":{"id":"reviewer:will-blair-bot","type":"human"},"after_hash":"sha256:d3e4cbb301f94e20904a9ab6cf3b5bfb3c6db20f27df42a91722d68746491c9e","before_hash":"sha256:null","caveats":["Manual findings require evidence review before scientific use."],"id":"vev_03ae13478d091c6d","kind":"finding.asserted","payload":{"proposal_id":"vpr_2ce006ffa5c100e5"},"reason":"Manual finding added to frontier state","schema":"vela.event.v0.1","signature":"a54f12845ee42936c29bea354c7c1440d38118a192650830ccdf82b50e3fe58940cdf2fe15efe9fff662f224ea83020f34ad14023a3f0340a1db0096363cfa0c","target":{"id":"vf_7b4bfdf919b22af5","type":"finding"},"timestamp":"2026-05-06T03:57:47.110337+00:00"},{"actor":{"id":"reviewer:will-blair-bot","type":"human"},"after_hash":"sha256:7a7acb64802250f7ee693fa7955acc6dc1920991b1684025ee70c0e3ee7667dc","before_hash":"sha256:071a69e12011a650deeb629d30a726896484e8e166becd85a7f4f93b73db9fc1","caveats":[],"id":"vev_03d96ee7a3a2d7a0","kind":"finding.caveated","payload":{"annotation_id":"ann_39b4b2c1f9816600","proposal_id":"vpr_6c5189e1748f9542","text":"Decision-console scope: ARIA/APOE4 risk is a stratification and monitoring constraint, not a standalone contraindication claim; interpret with current label criteria, MRI monitoring, anticoagulant context, and local eligibility rules."},"reason":"Decision-console scope: ARIA/APOE4 risk is a stratification and monitoring constraint, not a standalone contraindication claim; interpret with current label criteria, MRI monitoring, anticoagulant context, and local eligibility rules.","schema":"vela.event.v0.1","signature":"6cca0d85b4c1b7f20202050eae439f5bcb3e239680fe1aafebb8a300539b707e3be0796f6c5b47013994ee13de294305d968eb06cd2066e8ef754444a855f906","target":{"id":"vf_2e7192704f1767e4","type":"finding"},"timestamp":"2026-05-06T05:42:49.727537+00:00"},{"actor":{"id":"agent:bbb-curation-bot-2026-05-09","type":"human"},"after_hash":"sha256:5b7b36e3a0d57268122090ba3e35f763c545dcdb453644f21e633747fe426c2d","before_hash":"sha256:null","caveats":["Manual findings require evidence review before scientific use."],"id":"vev_0411c32d02ca00e7","kind":"finding.asserted","payload":{"proposal_id":"vpr_c066c6886d42f094"},"reason":"Manual finding added to frontier state","schema":"vela.event.v0.1","target":{"id":"vf_61249fb410ed2d52","type":"finding"},"timestamp":"2026-05-09T21:02:14.627834+00:00"},{"actor":{"id":"reviewer:will-blair-bot","type":"human"},"after_hash":"sha256:aa09239573833a1bafff78642186dbedd305d721f3188de64822081739ab7a71","before_hash":"sha256:eb97a3fd1f4a43ed54c7da794402fe8c2bbbfcd86308c62c832a867e24b86f76","caveats":[],"id":"vev_04967ad4df49dd95","kind":"finding.confidence_revised","payload":{"affected":0,"cascade_fired":true,"new_score":0.42,"previous_score":0.5,"proposal_id":"vpr_b4d3f58f831da9f6"},"reason":"Small pilot evidence lowers translation confidence until replicated.","schema":"vela.event.v0.1","signature":"bafa5a3dae0f7fab17e98b366f1a850d6cf6c75d6b7c6e25d90133a61bd115cd88fbe14da293d8ec58d66ad4b40c45899a4e9e808b3f041660fd58edb41f4909","target":{"id":"vf_56f893a9fe9651de","type":"finding"},"timestamp":"2026-05-06T03:57:54.204816+00:00"},{"actor":{"id":"reviewer:will-blair-bot","type":"human"},"after_hash":"sha256:null","before_hash":"sha256:null","caveats":[],"id":"vev_06ffd8c128c22ab5","kind":"artifact.asserted","payload":{"artifact":{"access_tier":"public","content_hash":"sha256:6f51d2f2f35b3c4e2150eb29383a1a5b48b45d55eba29afb567b8352d0ce48f1","created":"2026-05-06T07:24:06.126299+00:00","id":"va_eea2efa95b625e98","kind":"source_file","license":"public metadata; source records retain their own access terms","locator":".vela/artifact-blobs/sha256/6f51d2f2f35b3c4e2150eb29383a1a5b48b45d55eba29afb567b8352d0ce48f1","media_type":"application/json","metadata":{"frontier_id":"vfr_5076e7b3ff8e6b0f","schema":"vela.source-ingest-plan.v1"},"name":"Anti-amyloid source ingest catalog v1","provenance":{"authors":[],"citation_count":null,"doi":null,"extraction":{"extracted_at":"2026-05-06T07:24:06.126281+00:00","extractor_version":"0.54.0","method":"artifact_deposit","model":null,"model_version":null},"journal":null,"license":"public metadata; source records retain their own access terms","openalex_id":null,"pmc":null,"pmid":null,"review":null,"source_type":"database_record","title":"Anti-amyloid source ingest catalog v1","url":"https://github.com/vela-science/vela/tree/main/projects/anti-amyloid-translation/ingest/source-ingest-plan.v1.json","year":null},"retracted":false,"size_bytes":31430,"source_url":"https://github.com/vela-science/vela/tree/main/projects/anti-amyloid-translation/ingest/source-ingest-plan.v1.json","storage_mode":"local_blob","target_findings":["vf_45b4e018839586ea"]},"proposal_id":"vpr_ab6274bb91077941"},"reason":"source ingest catalog deposit","schema":"vela.event.v0.1","signature":"04ad93eac2f026b2b27c47471d8adb83b1d794a7a9b06a659978c93635c4c865cbfb10db53ffd4656eb5b4842de177f07866b32a8c0f3386fad9bf725645b101","target":{"id":"va_eea2efa95b625e98","type":"artifact"},"timestamp":"2026-05-06T07:24:06.142172+00:00"},{"actor":{"id":"reviewer:will-blair-bot","type":"human"},"after_hash":"sha256:258fe5fc70186c439794b17efbea7b9893f4b436977a4349121c444b4a0b6f1c","before_hash":"sha256:null","caveats":["Manual findings require evidence review before scientific use."],"id":"vev_0779c5ea8b12669a","kind":"finding.asserted","payload":{"proposal_id":"vpr_339ba6b774ad10b4"},"reason":"Manual finding added to frontier state","schema":"vela.event.v0.1","signature":"c4bd3f8c0663e78e1eee22dfc50a18f5bcfe51d778a7e3540a5babd7a74f67d15b0af0088a21d247d55b04b1fe728d7bc1e150941120cbc23e6b6895fcab710b","target":{"id":"vf_a9203e156f10cb62","type":"finding"},"timestamp":"2026-05-06T03:57:48.558891+00:00"},{"actor":{"id":"reviewer:will-blair-bot","type":"human"},"after_hash":"sha256:408c87a8359ca411c30ea97fa494c04a6e8bb830c38fcb76a7803c4ae313533b","before_hash":"sha256:null","caveats":["Manual findings require evidence review before scientific use."],"id":"vev_080ad2b24c0467de","kind":"finding.asserted","payload":{"proposal_id":"vpr_dcfc49f1d3d56d1d"},"reason":"Manual finding added to frontier state","schema":"vela.event.v0.1","signature":"d3bfcf6a9d8668a7d635c429dc94058a7360db58828cea87604b7d8b9c107dbecdb99858f0fa29ec907bcfe784e61a2903429a19ae2e528773dab129b1a78603","target":{"id":"vf_c0ab26a1a6a29290","type":"finding"},"timestamp":"2026-05-06T03:57:52.289312+00:00"},{"actor":{"id":"reviewer:will-blair-bot","type":"human"},"after_hash":"sha256:null","before_hash":"sha256:null","caveats":[],"id":"vev_0849176e3b2f21a6","kind":"artifact.asserted","payload":{"artifact":{"access_tier":"public","content_hash":"sha256:1fd31c3e10dd26faa78615b0e71f3f6a7d34fefea0561b54703ebadf057f5873","created":"2026-05-06T07:19:34.081992+00:00","id":"va_cdd2e1bde7e00e07","kind":"dataset","license":"public locator; data access requires NACC request and data use agreement","locator":".vela/artifact-blobs/sha256/1fd31c3e10dd26faa78615b0e71f3f6a7d34fefea0561b54703ebadf057f5873","media_type":"application/json","metadata":{"dataset":"NACC-UDS"},"name":"NACC Uniform Data Set access record","provenance":{"authors":[],"citation_count":null,"doi":null,"extraction":{"extracted_at":"2026-05-06T07:19:34.081975+00:00","extractor_version":"0.54.0","method":"artifact_deposit","model":null,"model_version":null},"journal":null,"license":"public locator; data access requires NACC request and data use agreement","openalex_id":null,"pmc":null,"pmid":null,"review":null,"source_type":"data_release","title":"National Alzheimer's Coordinating Center data request process","url":"https://www.naccdata.org/data-request-process/","year":null},"retracted":false,"size_bytes":533,"source_url":"https://www.naccdata.org/data-request-process/","storage_mode":"local_blob","target_findings":["vf_45b4e018839586ea"]},"proposal_id":"vpr_5ad8aa626eb0a4e6"},"reason":"dataset access locator deposit","schema":"vela.event.v0.1","signature":"b4f510ae94668ad7c14687f9ae6e67bd05b42c458492c08c557563430c9183633b724dc0545b679d5ff5e9fc0c39ca3926bc29d36bcc56c412064e0ec8992203","target":{"id":"va_cdd2e1bde7e00e07","type":"artifact"},"timestamp":"2026-05-06T07:19:34.098894+00:00"},{"actor":{"id":"reviewer:will-blair-bot","type":"human"},"after_hash":"sha256:aa9144c5c64bffa9da9caceb460a454b3225dd3a17cb36152b06911b4b2b3f71","before_hash":"sha256:null","caveats":["Manual findings require evidence review before scientific use."],"id":"vev_087d4d5ba8c45f80","kind":"finding.asserted","payload":{"proposal_id":"vpr_0996ef1dd134f055"},"reason":"Manual finding added to frontier state","schema":"vela.event.v0.1","signature":"811ad37bae4c4276d0d036aa998f0735571b1716962061d11a8c5d0648363f7fa78845e89a2cb343a53eff3e76d1e11ffca36244a7bd5dc936e65d71ff326205","target":{"id":"vf_29671540d388fc5d","type":"finding"},"timestamp":"2026-05-06T03:57:47.277902+00:00"},{"actor":{"id":"reviewer:will-blair-bot","type":"human"},"after_hash":"sha256:0d290a6ba3dc58ea4624b70019965a04ea620b4f4ee1f842370f9d0d81c741bd","before_hash":"sha256:null","caveats":["Manual findings require evidence review before scientific use."],"id":"vev_0aa8718efdf9be6a","kind":"finding.asserted","payload":{"proposal_id":"vpr_3915a57b568c833b"},"reason":"Manual finding added to frontier state","schema":"vela.event.v0.1","signature":"aa1032ac697b4828fbe5a0ca2d95f3c946721640cc7d9575f0059d51cebf0013296107299c651a49a465c07827b27f554497653acf0b6ef7207c6bb92e16ab0a","target":{"id":"vf_e0683bf56937bdc3","type":"finding"},"timestamp":"2026-05-06T03:57:51.280506+00:00"},{"actor":{"id":"reviewer:will-blair-bot","type":"human"},"after_hash":"sha256:371eb41fca8fdc726e72da26e9853741c5c12f156704c4a66b871f866a239dfa","before_hash":"sha256:null","caveats":["Manual findings require evidence review before scientific use."],"id":"vev_0bb55211bc66258d","kind":"finding.asserted","payload":{"proposal_id":"vpr_243c0195a9f529ae"},"reason":"Manual finding added to frontier state","schema":"vela.event.v0.1","signature":"4cf51ab1bd07d576436d3e6da86f18e1f7780d3afd5046991ac97c43b155ae68aad72730146162386f352a27ce6fbe1ae9c825f83a58af87feae9a1ac514000e","target":{"id":"vf_3dcfa7fb41b3b39c","type":"finding"},"timestamp":"2026-05-06T03:57:47.613442+00:00"},{"actor":{"id":"reviewer:will-blair","type":"human"},"after_hash":"sha256:d943e66707630efc5673308418633da46234639d14f8b8ed1e08042dc11ac500","before_hash":"sha256:a2ee4756e343c727cb61cf4f96619af9db8b8bd003a82bada5b36e2a0aea6dc5","caveats":[],"id":"vev_0c7e7a8485eae765","kind":"evidence_atom.locator_repaired","payload":{"locator":"title:Yamazaki et al., Brain 2019; Carrano et al., Antioxid Redox Signal 2011","proposal_id":"vpr_be998bec89553a72","source_id":"vs_80b7c2dc8cc0347b"},"reason":"Wave A.1 mechanical curation: copy parent source locator to evidence atom; substantive DOI verification deferred to human pass.","schema":"vela.event.v0.1","target":{"id":"vea_425a112a4b09fa12","type":"evidence_atom"},"timestamp":"2026-05-10T00:18:05.311136+00:00"},{"actor":{"id":"reviewer:will-blair-bot","type":"human"},"after_hash":"sha256:0b5e429b5fb39da59ca5af38c8687a458db2fdb6330274de4c4031ebc46f4ec4","before_hash":"sha256:null","caveats":["Manual findings require evidence review before scientific use."],"id":"vev_0d5c288b5b4b8275","kind":"finding.asserted","payload":{"proposal_id":"vpr_6e41d9c50cee5b6f"},"reason":"Manual finding added to frontier state","schema":"vela.event.v0.1","signature":"e3f9fa119d1e84e9a7be460802e6d24d7f6ea6f5cf0621296efd1de8267ecac8266170ff0719641328aed68c2ec9ca54af41b8b4a80479c35a38fe526b628e03","target":{"id":"vf_cc13f5d991f2c86c","type":"finding"},"timestamp":"2026-05-06T03:57:49.503886+00:00"},{"actor":{"id":"reviewer:will-blair-bot","type":"human"},"after_hash":"sha256:ebcd8d08c7a00303a5db6e29011a5e9fdf4b00dbbead96712392c2985ba5bd1a","before_hash":"sha256:148ca074f1ec5ddefcbe52fa9dd668fc6befcb91eb93a107a2d3f452fe8f59b5","caveats":[],"id":"vev_0db795e69ce3bc3a","kind":"finding.confidence_revised","payload":{"affected":0,"cascade_fired":true,"new_score":0.49,"previous_score":0.57,"proposal_id":"vpr_c6716e8617594005"},"reason":"Preclinical delivery improvement does not rescue failed clinical BACE programs.","schema":"vela.event.v0.1","signature":"f10dc1db1027d34ad2ed780c19cd58a845e75c26b9e645711c1027e1be2e40361f01219353bb46fe4a56a7b59eb87ad90f8d719e4c33db70009cb87896f2a00c","target":{"id":"vf_4f57348016eea37b","type":"finding"},"timestamp":"2026-05-06T03:57:54.265428+00:00"},{"actor":{"id":"reviewer:will-blair-bot","type":"human"},"after_hash":"sha256:1dcc3fc1bd4dbbc86156bb50a63592d2614b45634c8bb0aa3330d063d52eede2","before_hash":"sha256:null","caveats":["Manual findings require evidence review before scientific use."],"id":"vev_0ee4b716af63a106","kind":"finding.asserted","payload":{"proposal_id":"vpr_15312fab51cde813"},"reason":"Manual finding added to frontier state","schema":"vela.event.v0.1","signature":"06b16c980479b762cd4e410252858f5888de7d5e9c9fd3ee1c32a3c78320992b436c2d385c107bf9707fa531c178dd092c00ba7d37218e00730ad8660cc77905","target":{"id":"vf_3d254efae19793ea","type":"finding"},"timestamp":"2026-05-06T03:57:47.246015+00:00"},{"actor":{"id":"reviewer:will-blair-bot","type":"human"},"after_hash":"sha256:071a69e12011a650deeb629d30a726896484e8e166becd85a7f4f93b73db9fc1","before_hash":"sha256:02cb978d8e263daece2fe1d50e57ddf7c24ad1e6034e1935c63f9d5e6ccec101","caveats":[],"id":"vev_111c4cd0ae00fa3a","kind":"finding.caveated","payload":{"annotation_id":"ann_28f1f500c912654b","proposal_id":"vpr_7cd889d1f403723b","text":"Risk estimates should be read from current labels and trial safety tables before patient-level decisions."},"reason":"Risk estimates should be read from current labels and trial safety tables before patient-level decisions.","schema":"vela.event.v0.1","signature":"64dadb3fbb09b4d0b803a6703d111d00847bf46fd52e4e8a7f0e2aa9bf8873026bd1e548e31e33de72553418de28fc6a2f99508bb1a8d009fbaddfca72c26603","target":{"id":"vf_2e7192704f1767e4","type":"finding"},"timestamp":"2026-05-06T03:57:54.686576+00:00"},{"actor":{"id":"reviewer:will-blair-bot","type":"human"},"after_hash":"sha256:ecc97c8c137997d7264b406beda62332e9b1ea766a013e417cc921975fdb50e1","before_hash":"sha256:null","caveats":["Manual findings require evidence review before scientific use."],"id":"vev_127e79c7b6b3eedd","kind":"finding.asserted","payload":{"proposal_id":"vpr_091f37ad545a0d04"},"reason":"Manual finding added to frontier state","schema":"vela.event.v0.1","signature":"c10ca19792a63fbf8ecc25176eb513843cf6cdd6634f0db85310e706a2cbd9f92d09c28040cf2ff91663b4f508018878f96bd37f711c9b6cee406c941cc6610a","target":{"id":"vf_e46485c320b6b4ff","type":"finding"},"timestamp":"2026-05-06T03:57:48.407703+00:00"},{"actor":{"id":"reviewer:will-blair","type":"human"},"after_hash":"sha256:99b3c2368587b036fc7a91cb711fe83dde55ed79c78807c86f6bb3bbc03f400c","before_hash":"sha256:b628bb00729c6a2ecdd0cb38aeeecfe02dc080ed7d7e2bd9768793a480b69a1f","caveats":[],"id":"vev_13d1b9e687160b19","kind":"evidence_atom.locator_repaired","payload":{"locator":"title:Montagne et al., Nature 2020","proposal_id":"vpr_d1458c25977cc36f","source_id":"vs_afa51a429ac2eb12"},"reason":"Wave A.1 mechanical curation: copy parent source locator to evidence atom; substantive DOI verification deferred to human pass.","schema":"vela.event.v0.1","target":{"id":"vea_25118d0d51e7bb38","type":"evidence_atom"},"timestamp":"2026-05-10T00:18:04.759334+00:00"},{"actor":{"id":"reviewer:will-blair-bot","type":"human"},"after_hash":"sha256:698d95733f92bb3632ba682ad0bfe75c675f980b278afee7337d8d480138b9f3","before_hash":"sha256:null","caveats":["Manual findings require evidence review before scientific use."],"id":"vev_14d736c235160f48","kind":"finding.asserted","payload":{"proposal_id":"vpr_393c299e51a05923"},"reason":"Manual finding added to frontier state","schema":"vela.event.v0.1","signature":"96fdc92d09d198c436305c6f80c43477e0937801fa69fdd273647ca154d913c60275051115d52dc107c5bf8c17b6f7aa5fd8644207d6d5e35454e75821e93509","target":{"id":"vf_821c331e449f53b8","type":"finding"},"timestamp":"2026-05-06T03:57:48.467190+00:00"},{"actor":{"id":"reviewer:will-blair-bot","type":"human"},"after_hash":"sha256:null","before_hash":"sha256:null","caveats":[],"id":"vev_156305939f6743bc","kind":"artifact.asserted","payload":{"artifact":{"access_tier":"public","content_hash":"sha256:6968a768a5e938eeaca3f1ec7cfb6106bd82ab3081b1fcdbd82dc8474ff29ed7","created":"2026-05-06T03:57:56.404822+00:00","id":"va_f68397c4ccf707d1","kind":"clinical_trial_record","license":"ClinicalTrials.gov public record","locator":".vela/artifact-blobs/sha256/6968a768a5e938eeaca3f1ec7cfb6106bd82ab3081b1fcdbd82dc8474ff29ed7","media_type":"application/json","metadata":{"completion_date":"2018-12-20","conditions":["Asymptomatic Amyloid-positive"],"has_results":true,"interventions":["Atabecestat, 5 mg","Atabecestat, 25 mg","Placebo"],"nct_id":"NCT02569398","overall_status":"TERMINATED","phases":["PHASE2","PHASE3"],"primary_outcomes":["Change From Baseline in Preclinical Alzheimer Cognitive Composite (PACC) Score at Endpoint (Month 24)"],"retrieved_at":"2026-05-06T03:57:56.404795+00:00","source_api":"clinicaltrials.gov-v2","start_date":"2015-10-29"},"name":"An Efficacy and Safety Study of Atabecestat in Participants Who Are Asymptomatic at Risk for Developing Alzheimer's Dementia","provenance":{"authors":[],"citation_count":null,"doi":null,"extraction":{"extracted_at":"2026-05-06T03:57:56.404813+00:00","extractor_version":"0.54.0","method":"artifact_deposit","model":null,"model_version":null},"journal":null,"license":"ClinicalTrials.gov public record","openalex_id":null,"pmc":null,"pmid":null,"review":null,"source_type":"clinical_trial","title":"An Efficacy and Safety Study of Atabecestat in Participants Who Are Asymptomatic at Risk for Developing Alzheimer's Dementia","url":"https://clinicaltrials.gov/study/NCT02569398","year":null},"retracted":false,"size_bytes":73196,"source_url":"https://clinicaltrials.gov/study/NCT02569398","storage_mode":"local_blob","target_findings":["vf_3d75299a343a2fc8"]},"proposal_id":"vpr_1b8eb3f9f63b9a75"},"reason":"public trial record for anti-amyloid frontier (NCT02569398)","schema":"vela.event.v0.1","signature":"26d7e16ecf694f72cb7a006744c2f1a1c8f52fb18f3c1683cd86fb773e5c9f5d5278bea841fb89e33a3d54761c9f5df5ca63ddd8644e5fdd5838daa8a1a47705","target":{"id":"va_f68397c4ccf707d1","type":"artifact"},"timestamp":"2026-05-06T03:57:56.418224+00:00"},{"actor":{"id":"reviewer:will-blair-bot","type":"human"},"after_hash":"sha256:3d38df642d6869f46840fed9d95e70141b2ede9900e01802a4f7a21ec76de186","before_hash":"sha256:null","caveats":["Manual findings require evidence review before scientific use."],"id":"vev_1606a2f48d2f6b46","kind":"finding.asserted","payload":{"proposal_id":"vpr_b61bd5d4f01f67c8"},"reason":"Manual finding added to frontier state","schema":"vela.event.v0.1","signature":"17870cf14a5e5de8b6f87a38ecca27f8307b91e79f554a1fb77c172cf8dfe1face7d0fe196e6e3e62059fd95d9505d8cb440c664464bc5d8a26d5fb794115302","target":{"id":"vf_3ea4b6ad3a6a1bc9","type":"finding"},"timestamp":"2026-05-06T03:57:48.089979+00:00"},{"actor":{"id":"reviewer:will-blair-bot","type":"human"},"after_hash":"sha256:c8f1a026b3ee42abbe94e797533a9d2b0746a40910a8a1c845a49682f5c235cc","before_hash":"sha256:null","caveats":["Manual findings require evidence review before scientific use."],"id":"vev_16fd2ce15417577f","kind":"finding.asserted","payload":{"proposal_id":"vpr_a128deb48e5f4186"},"reason":"Manual finding added to frontier state","schema":"vela.event.v0.1","signature":"a38f287e5d214637fd324de924017aedacf327e06a39ff0ea9c705e407dc400b341de225ef8d38b495249d9293b4240de28d0bbad7839198ea648387c80d4e0f","target":{"id":"vf_3ef6135eee626ee1","type":"finding"},"timestamp":"2026-05-06T03:57:47.456275+00:00"},{"actor":{"id":"reviewer:will-blair-bot","type":"human"},"after_hash":"sha256:300380c02c30df82207bb6e8c726de5ef721f42d3cf1996f92694cc1b70349fd","before_hash":"sha256:null","caveats":["Manual findings require evidence review before scientific use."],"id":"vev_171fad180bf3c45b","kind":"finding.asserted","payload":{"proposal_id":"vpr_5c8667776a610821"},"reason":"Manual finding added to frontier state","schema":"vela.event.v0.1","signature":"3736f54b9656554539f0cfc9d4d31a372f49878547397f2fae73fb6ae7356c382eb5b1bccfd0cc65820f566d5173cc291e2fcf45e4c232c6045e794f34a10c01","target":{"id":"vf_b56e4c6ab7f42e14","type":"finding"},"timestamp":"2026-05-06T03:57:52.404584+00:00"},{"actor":{"id":"reviewer:will-blair-bot","type":"human"},"after_hash":"sha256:null","before_hash":"sha256:null","caveats":[],"id":"vev_17f506cc91f98c55","kind":"artifact.asserted","payload":{"artifact":{"access_tier":"public","content_hash":"sha256:4a4ce050efabc1812f8c50fb7628d74ce9e53b72d92cf2fb2d049a35e74198d5","created":"2026-05-06T05:20:59.066272+00:00","id":"va_e3aa793bcc15732a","kind":"registry_record","license":"CC0-1.0; derived Vela review artifact","locator":".vela/artifact-blobs/sha256/4a4ce050efabc1812f8c50fb7628d74ce9e53b72d92cf2fb2d049a35e74198d5","media_type":"application/json","metadata":{"schema":"vela.source-verification.v1"},"name":"Anti-amyloid source verification packet v1","provenance":{"authors":[],"citation_count":null,"doi":null,"extraction":{"extracted_at":"2026-05-06T05:20:59.066192+00:00","extractor_version":"0.54.0","method":"artifact_deposit","model":null,"model_version":null},"journal":null,"license":"CC0-1.0; derived Vela review artifact","openalex_id":null,"pmc":null,"pmid":null,"review":null,"source_type":"database_record","title":"Anti-amyloid source verification packet v1","url":"https://vela-site.fly.dev/workbench?vfr=vfr_5076e7b3ff8e6b0f","year":null},"retracted":false,"size_bytes":2748,"source_url":"https://vela-site.fly.dev/workbench?vfr=vfr_5076e7b3ff8e6b0f","storage_mode":"local_blob","target_findings":["vf_421b336a4bf3e428","vf_6e3f22f4cb7f83a5"]},"proposal_id":"vpr_4668eb22659eed7d"},"reason":"source verification packet","schema":"vela.event.v0.1","signature":"ba4a1b09d00192dd3ffdd6864aedf53580b83e7fe6f5c2b949da29aecc364ef48aff367f1fe41b8d8f1eb2fd7f710975734519341aecfe7eca3a01eff45a4e0f","target":{"id":"va_e3aa793bcc15732a","type":"artifact"},"timestamp":"2026-05-06T05:20:59.110833+00:00"},{"actor":{"id":"reviewer:will-blair-bot","type":"human"},"after_hash":"sha256:232e045687ad8ad5a15db1f7aeda63508e3776824c65643823933362bce59ac1","before_hash":"sha256:null","caveats":["Manual findings require evidence review before scientific use."],"id":"vev_181ae8b59b4826cd","kind":"finding.asserted","payload":{"proposal_id":"vpr_f3a6eed6c7cf8978"},"reason":"Manual finding added to frontier state","schema":"vela.event.v0.1","signature":"51c7b64cb83238fc72339406cd1c21ce7942e14857cdb12da4b4c6c36327cb62491e826ba90939b6aa7de529e69af7e770a45bb342a234612f53f7ac43126f0e","target":{"id":"vf_e2554d6d7ec32686","type":"finding"},"timestamp":"2026-05-06T03:57:47.551087+00:00"},{"actor":{"id":"reviewer:will-blair-bot","type":"human"},"after_hash":"sha256:fed3ecba7697075dbce510058bc72bd82dc76dbed92fee2e450a23ac0bdbd9b0","before_hash":"sha256:null","caveats":["Manual findings require evidence review before scientific use."],"id":"vev_1847bd131d7fa899","kind":"finding.asserted","payload":{"proposal_id":"vpr_b2e493c14551eee5"},"reason":"Manual finding added to frontier state","schema":"vela.event.v0.1","signature":"f43df13abc95844c0eb4728c285eac386235c86d0f9d0e0386f43438a95d899d9baf363d5721d0b564a4d6217b923f557d1c9df3a3b9e2fa85b6ea7591534602","target":{"id":"vf_15e91a7cbffb3d34","type":"finding"},"timestamp":"2026-05-06T03:57:49.745658+00:00"},{"actor":{"id":"reviewer:will-blair-bot","type":"human"},"after_hash":"sha256:3bc68c762fe9d207e34eff4345160fdcce6f75fbb27d79ed4566e8aa3ce1c9a1","before_hash":"sha256:null","caveats":["Manual findings require evidence review before scientific use."],"id":"vev_184863467acbd051","kind":"finding.asserted","payload":{"proposal_id":"vpr_a901f7375eedf9be"},"reason":"Manual finding added to frontier state","schema":"vela.event.v0.1","signature":"6850ad555a74f5793a18db409c5ff72e5636128f230d9b672b7c0cd0d85f39f97f9be63c273d782fd53f69ce7c0c488aa09f4a682315c0b8e2464a68303a2201","target":{"id":"vf_247ab84f7a601b89","type":"finding"},"timestamp":"2026-05-06T03:57:47.164665+00:00"},{"actor":{"id":"reviewer:will-blair-bot","type":"human"},"after_hash":"sha256:82a0950a718ef730747c14c1ab9f58da970fe97f6df2ef994fc21a0a45c9bb18","before_hash":"sha256:null","caveats":["Manual findings require evidence review before scientific use."],"id":"vev_18f73ddc0f0ede90","kind":"finding.asserted","payload":{"proposal_id":"vpr_ad88a20f3ac37c0d"},"reason":"Manual finding added to frontier state","schema":"vela.event.v0.1","signature":"c2f758a4fdae1a17673427e6c0754ae4706beca59675191bb3183632f90c8de3e976fa4aeb33813fd03e2448ca064db4a32c01cb6fde858e6c6178870e321f09","target":{"id":"vf_1ee3be6d4e3dbe33","type":"finding"},"timestamp":"2026-05-06T03:57:48.232803+00:00"},{"actor":{"id":"reviewer:will-blair-bot","type":"human"},"after_hash":"sha256:null","before_hash":"sha256:null","caveats":["Source adapter output is registry metadata, not a clinical conclusion.","Truth-changing frontier updates require reviewer acceptance."],"id":"vev_1b4cf61b3dcb3968","kind":"artifact.asserted","payload":{"artifact":{"access_tier":"public","content_hash":"sha256:596bf7eaffdb42a89796033b6ce655ee197312f00a2d3e26a926e75a9d5a774f","created":"2026-05-06T19:41:57.152768+00:00","id":"va_f7a3b488793a0a01","kind":"clinical_trial_record","license":"public source locator; no restricted bytes deposited","locator":"https://clinicaltrials.gov/study/NCT05738486","media_type":"application/json","metadata":{"adapter":"clinicaltrials-gov-v2","api_url":"https://clinicaltrials.gov/api/v2/studies/NCT05738486","artifact_packet_id":"cap_818a078e8b9d8ed6","entry_id":"ct-donanemab-trailblazer-alz-6","external_artifact_id":"clinicaltrials_gov_v2_NCT05738486","nct_id":"NCT05738486","new_content_hash":"sha256:596bf7eaffdb42a89796033b6ce655ee197312f00a2d3e26a926e75a9d5a774f","old_artifact_id":"va_17728f513970ada4","old_content_hash":"sha256:3db879e2081590576dd8e749efbc9487eba9eb4930381dfde3c4957f530295ea","parent_artifact_ids":["sir_68a1577de35d0d91_manifest"],"producer_agent":"adapter:clinicaltrials-gov-v2","retrieved_at":"2026-05-06T19:41:56.546984+00:00","run_id":"sir_68a1577de35d0d91","source_url":"https://clinicaltrials.gov/study/NCT05738486","target_findings":["vf_994f2bcb18f2aeeb"],"topic":"Anti-amyloid translation in Alzheimer's disease"},"name":"ClinicalTrials.gov NCT05738486 · A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)","provenance":{"authors":[{"name":"ClinicalTrials.gov API v2 source adapter","orcid":null}],"citation_count":null,"doi":null,"extraction":{"extracted_at":"2026-05-06T19:41:57.152724+00:00","extractor_version":"vela/0.55.0","method":"artifact_to_state_import","model":"adapter:clinicaltrials-gov-v2","model_version":null},"journal":null,"openalex_id":null,"pmc":null,"pmid":null,"publisher":"artifact packet","review":{"corrections":[],"reviewed":false,"reviewed_at":null,"reviewer":null},"source_type":"clinical_trial","title":"cap_818a078e8b9d8ed6 · ClinicalTrials.gov NCT05738486 · A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)","url":"https://clinicaltrials.gov/study/NCT05738486","year":null},"retracted":false,"source_url":"https://clinicaltrials.gov/study/NCT05738486","storage_mode":"remote","target_findings":["vf_994f2bcb18f2aeeb"]},"proposal_id":"vpr_7cbdb92d91c7980a"},"reason":"Import artifact clinicaltrials_gov_v2_NCT05738486 from artifact packet cap_818a078e8b9d8ed6","schema":"vela.event.v0.1","signature":"d67188ceac8e188cbd06f504780bcec4f4023d197f75133bde3bfa4ff15b6d03310790fbc338ce14ad1286d86fa1f4dfc26b906c477ad6ddabaee92827a2f208","target":{"id":"va_f7a3b488793a0a01","type":"artifact"},"timestamp":"2026-05-06T19:41:57.203588+00:00"},{"actor":{"id":"reviewer:will-blair-bot","type":"human"},"after_hash":"sha256:null","before_hash":"sha256:null","caveats":[],"id":"vev_1cd0e4ed02fabeaa","kind":"artifact.asserted","payload":{"artifact":{"access_tier":"public","content_hash":"sha256:530f762a410695f8ec3960b56d90841649fa5742590c1ca5b451944b65ff3fb7","created":"2026-05-06T03:57:56.241540+00:00","id":"va_a46c919127c0a005","kind":"clinical_trial_record","license":"ClinicalTrials.gov public record","locator":".vela/artifact-blobs/sha256/530f762a410695f8ec3960b56d90841649fa5742590c1ca5b451944b65ff3fb7","media_type":"application/json","metadata":{"completion_date":"2018-09-28","conditions":["Alzheimer's Disease"],"has_results":true,"interventions":["Lanabecestat","Placebo"],"nct_id":"NCT02783573","overall_status":"TERMINATED","phases":["PHASE3"],"primary_outcomes":["Change From Baseline in Alzheimer´s Disease Assessment Scale- Cognitive Subscale (ADAS-Cog13) Score"],"retrieved_at":"2026-05-06T03:57:56.241514+00:00","source_api":"clinicaltrials.gov-v2","start_date":"2016-07-01"},"name":"A Study of Lanabecestat (LY3314814) in Participants With Mild Alzheimer's Disease Dementia","provenance":{"authors":[],"citation_count":null,"doi":null,"extraction":{"extracted_at":"2026-05-06T03:57:56.241532+00:00","extractor_version":"0.54.0","method":"artifact_deposit","model":null,"model_version":null},"journal":null,"license":"ClinicalTrials.gov public record","openalex_id":null,"pmc":null,"pmid":null,"review":null,"source_type":"clinical_trial","title":"A Study of Lanabecestat (LY3314814) in Participants With Mild Alzheimer's Disease Dementia","url":"https://clinicaltrials.gov/study/NCT02783573","year":null},"retracted":false,"size_bytes":192123,"source_url":"https://clinicaltrials.gov/study/NCT02783573","storage_mode":"local_blob","target_findings":["vf_0767356cc73a6387"]},"proposal_id":"vpr_3834e48b68d878ea"},"reason":"public trial record for anti-amyloid frontier (NCT02783573)","schema":"vela.event.v0.1","signature":"806a7f564a66147bee8b909f842d314bfee2bd2a8ee55826633e689ee7e6620509ce5ae28625da88f1814675ce353bf1b09173b74317e944e668feb32e4c160d","target":{"id":"va_a46c919127c0a005","type":"artifact"},"timestamp":"2026-05-06T03:57:56.254624+00:00"},{"actor":{"id":"reviewer:will-blair-bot","type":"human"},"after_hash":"sha256:04dc7f1c7720e7d20fbb837ba7ef820c94e23ac803015e9b467ea50fcbfe70a4","before_hash":"sha256:null","caveats":["Manual findings require evidence review before scientific use."],"id":"vev_1ffd6ed1945c369a","kind":"finding.asserted","payload":{"proposal_id":"vpr_557b5bc4cde937ca"},"reason":"Manual finding added to frontier state","schema":"vela.event.v0.1","signature":"4383afd3bd83d2380b86bc756e81a1177d3000f992a788dbdd80e99f97b50b5cfa6997e4825b67501428abcdd61e033355280883a6e7d86445f998bff1ad1b0c","target":{"id":"vf_812f09f1fd585c2d","type":"finding"},"timestamp":"2026-05-06T03:57:48.033982+00:00"},{"actor":{"id":"reviewer:will-blair-bot","type":"human"},"after_hash":"sha256:null","before_hash":"sha256:null","caveats":[],"id":"vev_20c2ad5da6566119","kind":"artifact.asserted","payload":{"artifact":{"access_tier":"public","content_hash":"sha256:3d8779ac2a1c22c37856b6ef26e397383a5cd0e3ed2d88beec7cedb43685d6ed","created":"2026-05-06T07:18:23.305579+00:00","id":"va_18d2abe7cfcd2dcf","kind":"clinical_trial_record","license":"ClinicalTrials.gov public record","locator":".vela/artifact-blobs/sha256/3d8779ac2a1c22c37856b6ef26e397383a5cd0e3ed2d88beec7cedb43685d6ed","media_type":"application/json","metadata":{"completion_date":"2027-08-18","conditions":["Alzheimer's Disease"],"has_results":false,"interventions":["E2814","Lecanemab","Placebo"],"nct_id":"NCT06602258","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_outcomes":["Change From Baseline in CSF MTBR-tau-243 at 6 Months"],"retrieved_at":"2026-05-06T07:18:23.305540+00:00","source_api":"clinicaltrials.gov-v2","start_date":"2024-09-30"},"name":"A Study of E2814 With Concurrent Lecanemab Treatment in Participants With Early Alzheimer's Disease","provenance":{"authors":[],"citation_count":null,"doi":null,"extraction":{"extracted_at":"2026-05-06T07:18:23.305563+00:00","extractor_version":"0.54.0","method":"artifact_deposit","model":null,"model_version":null},"journal":null,"license":"ClinicalTrials.gov public record","openalex_id":null,"pmc":null,"pmid":null,"review":null,"source_type":"clinical_trial","title":"A Study of E2814 With Concurrent Lecanemab Treatment in Participants With Early Alzheimer's Disease","url":"https://clinicaltrials.gov/study/NCT06602258","year":null},"retracted":false,"size_bytes":19586,"source_url":"https://clinicaltrials.gov/study/NCT06602258","storage_mode":"local_blob","target_findings":["vf_2b10fee64b9970af"]},"proposal_id":"vpr_d500d9b4519ded01"},"reason":"E2814 with concurrent lecanemab registry import","schema":"vela.event.v0.1","signature":"dfdea6c173ab42f503da045393b8b86c7b725a3adaf3724b852077e4064e8c677b494e2a4123aaf8d807c1feb0d170b904391a49bfe4cedd5ea26da82c7f8206","target":{"id":"va_18d2abe7cfcd2dcf","type":"artifact"},"timestamp":"2026-05-06T07:18:23.321536+00:00"},{"actor":{"id":"reviewer:will-blair-bot","type":"human"},"after_hash":"sha256:null","before_hash":"sha256:null","caveats":[],"id":"vev_232f50c368576f26","kind":"artifact.asserted","payload":{"artifact":{"access_tier":"public","content_hash":"sha256:7ab99465b866c1fe3bb2d66f6d243c1f21ba4db6d84cf800b10af0d9a23143a3","created":"2026-05-06T07:19:34.017682+00:00","id":"va_9a993982e87b48cf","kind":"registry_record","license":"public locator; source materials retain EMA terms","locator":".vela/artifact-blobs/sha256/7ab99465b866c1fe3bb2d66f6d243c1f21ba4db6d84cf800b10af0d9a23143a3","media_type":"application/json","metadata":{"agency":"EMA","drug":"donanemab"},"name":"Kisunla EPAR and EU risk minimisation materials","provenance":{"authors":[],"citation_count":null,"doi":null,"extraction":{"extracted_at":"2026-05-06T07:19:34.017666+00:00","extractor_version":"0.54.0","method":"artifact_deposit","model":null,"model_version":null},"journal":null,"license":"public locator; source materials retain EMA terms","openalex_id":null,"pmc":null,"pmid":null,"review":null,"source_type":"database_record","title":"European Medicines Agency EPAR: Kisunla","url":"https://www.ema.europa.eu/en/medicines/human/EPAR/kisunla","year":null},"retracted":false,"size_bytes":524,"source_url":"https://www.ema.europa.eu/en/medicines/human/EPAR/kisunla","storage_mode":"local_blob","target_findings":["vf_421b336a4bf3e428"]},"proposal_id":"vpr_6852390f45ba00c5"},"reason":"EU regulatory locator deposit","schema":"vela.event.v0.1","signature":"9be0649f0ddd085a5d6b2a4fd24bd76800fb902ac4c8193f903be0adab21474086a642af120e63438d344c3b010dd206f73434c523df9307609d8fe927976609","target":{"id":"va_9a993982e87b48cf","type":"artifact"},"timestamp":"2026-05-06T07:19:34.033698+00:00"},{"actor":{"id":"reviewer:will-blair-bot","type":"human"},"after_hash":"sha256:34bd2ae900ba16ea4a46df368accf335a2d8a607a9d40f3036385a9a707e3cd8","before_hash":"sha256:null","caveats":["Manual findings require evidence review before scientific use."],"id":"vev_23a0799dd07bc47b","kind":"finding.asserted","payload":{"proposal_id":"vpr_6ac5c21b4e881d32"},"reason":"Manual finding added to frontier state","schema":"vela.event.v0.1","signature":"1985dbe33e93aaf84c69e11cfb42ff18f1560b7b121c1e4d258ec5b956c2840e9d967ee41502ca59a8bed07c14f83ae3d09ea728b8324710e0ecc72c695bd70e","target":{"id":"vf_3e548b0a1c8ee3b2","type":"finding"},"timestamp":"2026-05-06T03:57:49.788371+00:00"},{"actor":{"id":"reviewer:will-blair-bot","type":"human"},"after_hash":"sha256:d4804879f330d46739d21563680e38e28e8d95272ae57e87f7ed4a1b9c6208e9","before_hash":"sha256:3a48a56d64e79ae2074c9a8d00a8a5305446512720fb7c5fdfcb2d81811824a7","caveats":[],"id":"vev_256faa62a301a60c","kind":"finding.reviewed","payload":{"proposal_id":"vpr_da34872d64ddd2c9","status":"contested"},"reason":"Reviewed as amyloid-pathway translation tension, not as a direct antibody contradiction.","schema":"vela.event.v0.1","signature":"249bcf79df7ca10e4edddfac8f3714120c0819d559c7798688cdbf0e9c0e9b818fdc5435832149e1008924ec5172939d1916685b9978cc2a55bbc7338959c200","target":{"id":"vf_03875dbe6be66b00","type":"finding"},"timestamp":"2026-05-06T03:57:53.974696+00:00"},{"actor":{"id":"reviewer:will-blair-bot","type":"human"},"after_hash":"sha256:d9eafd0e48f499c3d87c12edbf365c0ed7d3dd0a332d227459bb3964b5648ec8","before_hash":"sha256:null","caveats":["Manual findings require evidence review before scientific use."],"id":"vev_265aea70f6dcd066","kind":"finding.asserted","payload":{"proposal_id":"vpr_58d3076bd3291e84"},"reason":"Manual finding added to frontier state","schema":"vela.event.v0.1","signature":"dd43376ec89d3488a722d546f696c6c210ee82ab6ea355071ea969a6677e1f5a6168d27ed1a4b16b866d2847201e56bcca741f487bc892f619f4e1de28639602","target":{"id":"vf_901cc5b7f2eaef25","type":"finding"},"timestamp":"2026-05-06T03:57:48.820830+00:00"},{"actor":{"id":"reviewer:will-blair-bot","type":"human"},"after_hash":"sha256:c7e13dac52a42086ac8d4ad02811e576ce722c1be38ad11b2b698e01af36669c","before_hash":"sha256:null","caveats":["Manual findings require evidence review before scientific use."],"id":"vev_26b01ba5a1399d46","kind":"finding.asserted","payload":{"proposal_id":"vpr_f665d8023056c5fd"},"reason":"Manual finding added to frontier state","schema":"vela.event.v0.1","signature":"76649f3165154839f8b7ac448a92a92601d5d9fd5fdf4d0f95b1f69265e0d5e543cbc9721923d642dfce2692b5ab17758446ed422c6a61ab6d7bacde013fa10f","target":{"id":"vf_3d75299a343a2fc8","type":"finding"},"timestamp":"2026-05-06T03:57:47.189348+00:00"},{"actor":{"id":"reviewer:will-blair-bot","type":"human"},"after_hash":"sha256:null","before_hash":"sha256:null","caveats":[],"id":"vev_271c0aea117c2454","kind":"artifact.asserted","payload":{"artifact":{"access_tier":"public","content_hash":"sha256:0bdfe869964f895c5ad8a8bb45f015f47d916b522d7934bb63dc39195ca89176","created":"2026-05-06T08:30:00.346372+00:00","id":"va_e04a8440ec036a69","kind":"source_file","license":"PubMed metadata public; publisher article and supplements retain journal terms","locator":".vela/artifact-blobs/sha256/0bdfe869964f895c5ad8a8bb45f015f47d916b522d7934bb63dc39195ca89176","media_type":"application/json","metadata":{"ingest_entry_id":"pub-trailblazer-alz-2-primary","pmid":"37459141"},"name":"TRAILBLAZER-ALZ 2 primary publication PubMed metadata","provenance":{"authors":[],"citation_count":null,"doi":"10.1001/jama.2023.13239","extraction":{"extracted_at":"2026-05-06T08:30:00.346349+00:00","extractor_version":"0.54.0","method":"artifact_deposit","model":null,"model_version":null},"journal":null,"license":"PubMed metadata public; publisher article and supplements retain journal terms","openalex_id":null,"pmc":null,"pmid":null,"review":null,"source_type":"database_record","title":"Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial","url":"https://pubmed.ncbi.nlm.nih.gov/37459141/","year":null},"retracted":false,"size_bytes":3583,"source_url":"https://pubmed.ncbi.nlm.nih.gov/37459141/","storage_mode":"local_blob","target_findings":["vf_7b4bfdf919b22af5","vf_3bbf2c4761c9867f"]},"proposal_id":"vpr_d69610e61f9991a5"},"reason":"artifact deposit","schema":"vela.event.v0.1","signature":"41b40f2e3b8737169edbb603406d30ca989a9aed6676b59bcd09530319fca7c02ffe9f5ed0d05b189ec4934d8b93cb35456c30603e11c185c7feeecbe3d8d204","target":{"id":"va_e04a8440ec036a69","type":"artifact"},"timestamp":"2026-05-06T08:30:00.359825+00:00"},{"actor":{"id":"agent:vela-curation-bot-2026-05-09","type":"human"},"after_hash":"sha256:b0d49f727a792e774d882a5434f6c5afd5932a663c1b61c980b22639e94e4efd","before_hash":"sha256:5f6b0b82c498986b0732fb229c9aa29dfc80d624afdf4a9b983ecc99bdc12a50","caveats":[],"id":"vev_275b9104a902a559","kind":"finding.reviewed","payload":{"proposal_id":"vpr_bc40e0ba80773b34","status":"accepted"},"reason":"ARIA (amyloid-related imaging abnormalities) including edema (ARIA-E) and hemosiderin (ARIA-H) is a well-established class effect of anti-Aβ antibodies, especially in APOE4 homozygotes. Agent-drafted accept; eligible for human re-review.","schema":"vela.event.v0.1","target":{"id":"vf_3ef6135eee626ee1","type":"finding"},"timestamp":"2026-05-09T21:33:40.080288+00:00"},{"actor":{"id":"reviewer:will-blair-bot","type":"human"},"after_hash":"sha256:8a2f579ca3888aa7f2af85291b8ca109a599e3484af01df5b5691655c53c355a","before_hash":"sha256:aa9144c5c64bffa9da9caceb460a454b3225dd3a17cb36152b06911b4b2b3f71","caveats":[],"id":"vev_28f131f360edfb4e","kind":"finding.reviewed","payload":{"proposal_id":"vpr_52272470ae065dbd","status":"needs_revision"},"reason":"Threshold differs by disease stage and stakeholder; keep as review lead.","schema":"vela.event.v0.1","signature":"36834c49f343bd6eaf7576eb5ab20806ffbeb3f83c4b804134f5c18f436e01ec970ed8402548f416972b7ee098a59ddfdaffa168c6ab6c0c5885fe16135c1c09","target":{"id":"vf_29671540d388fc5d","type":"finding"},"timestamp":"2026-05-06T03:57:53.750366+00:00"},{"actor":{"id":"reviewer:will-blair-bot","type":"human"},"after_hash":"sha256:10a1833e135c276f8d9226294bd79a33bef62fc84999d981ae5489caac6e28e4","before_hash":"sha256:null","caveats":["ScienceClaw-shaped packet used as source material, not accepted truth.","Locators are public source pointers; no restricted PDFs or private datasets are deposited.","Agent-generated synthesis; requires reviewer acceptance before entering frontier state.","Agent output is source material until reviewer acceptance."],"id":"vev_292de355de0c3b02","kind":"finding.asserted","payload":{"proposal_id":"vpr_1a553b43b6cc1262"},"reason":"Candidate claim sc_claim_benefit_risk_bound imported from artifact packet cap_anti_amyloid_scienceclaw_demo","schema":"vela.event.v0.1","signature":"92c7faa3d51da58cf37bde66d16f9513af3fc5763740ea76f46622ab8009764ced56e1cd3f8b343e5b8d07523173cfee6b231a5df729a0b93d3e97e331859407","target":{"id":"vf_8f771d0c7c3c3630","type":"finding"},"timestamp":"2026-05-06T17:58:11.680930+00:00"},{"actor":{"id":"reviewer:will-blair-bot","type":"human"},"after_hash":"sha256:172d12b2fc6c8bdb66e71b8012b74fbba0c0710c5c860e3219e1ab4bb9cbd65f","before_hash":"sha256:null","caveats":["Manual findings require evidence review before scientific use."],"id":"vev_29613cacc3935e3d","kind":"finding.asserted","payload":{"proposal_id":"vpr_fe5141c34390f678"},"reason":"Manual finding added to frontier state","schema":"vela.event.v0.1","signature":"fe8384665886da8a535b1c6e30316dcc8672ad6c2049439bf3d8276676762c196b82647f55c6411e1269e3cab38c50ca7ee4570d23949791f4e2f0fc6b9e4102","target":{"id":"vf_7b7a150ec0cc7288","type":"finding"},"timestamp":"2026-05-06T03:57:48.062175+00:00"},{"actor":{"id":"reviewer:will-blair-bot","type":"human"},"after_hash":"sha256:null","before_hash":"sha256:null","caveats":[],"id":"vev_2a3d41344c0ea5d3","kind":"artifact.asserted","payload":{"artifact":{"access_tier":"public","content_hash":"sha256:4fa96cb9b4b03772ad169b30113d48dd976299676ed3f74c44690f863cd0944f","created":"2026-05-06T05:46:46.144909+00:00","id":"va_3ff23aa8dca0039d","kind":"source_file","license":"public metadata; source locators only","locator":".vela/artifact-blobs/sha256/4fa96cb9b4b03772ad169b30113d48dd976299676ed3f74c44690f863cd0944f","media_type":"application/json","name":"Decision brief projection v1 with review trails","provenance":{"authors":[],"citation_count":null,"doi":null,"extraction":{"extracted_at":"2026-05-06T05:46:46.144824+00:00","extractor_version":"0.54.0","method":"artifact_deposit","model":null,"model_version":null},"journal":null,"license":"public metadata; source locators only","openalex_id":null,"pmc":null,"pmid":null,"review":null,"source_type":"database_record","title":"Anti-amyloid decision brief projection v1 with review trails","url":"https://github.com/vela-science/vela/tree/main/projects/anti-amyloid-translation/decision/decision-brief.v1.json","year":null},"retracted":false,"size_bytes":12019,"source_url":"https://github.com/vela-science/vela/tree/main/projects/anti-amyloid-translation/decision/decision-brief.v1.json","storage_mode":"local_blob","target_findings":["vf_9ded3333a52f3e58","vf_7b4bfdf919b22af5","vf_2e7192704f1767e4","vf_03875dbe6be66b00","vf_29671540d388fc5d","vf_afddbeabc19efa09"]},"proposal_id":"vpr_39a64daa139d6c81"},"reason":"decision projection updated with reviewed correction paths","schema":"vela.event.v0.1","signature":"ea2d0eaf4f610c6f18d42584e23e6c561824ac42744cb04cc333113028892ce5d2850c6c52e4b07b0cdfe1103c9cf6bf0f2714990e956a1ca8b6e1ac8b7ff403","target":{"id":"va_3ff23aa8dca0039d","type":"artifact"},"timestamp":"2026-05-06T05:46:46.192903+00:00"},{"actor":{"id":"reviewer:will-blair-bot","type":"human"},"after_hash":"sha256:02cb978d8e263daece2fe1d50e57ddf7c24ad1e6034e1935c63f9d5e6ccec101","before_hash":"sha256:null","caveats":["Manual findings require evidence review before scientific use."],"id":"vev_2b4bf0ab6091d328","kind":"finding.asserted","payload":{"proposal_id":"vpr_c165a37b0cf53a3b"},"reason":"Manual finding added to frontier state","schema":"vela.event.v0.1","signature":"a464e443a307e6973bb93447d55283e2d72ee4ad7d6add094a6cda7e6dac1f3823aa2cee3b6fd590175cd6d4180c0f0899b2233e0202218437bfe9a5c05af60e","target":{"id":"vf_2e7192704f1767e4","type":"finding"},"timestamp":"2026-05-06T03:57:47.229573+00:00"},{"actor":{"id":"reviewer:will-blair-bot","type":"human"},"after_hash":"sha256:dc4c19b1bb1457fde94ed62c7fe31c833425235b7defb7e0fe2cd569b13841cc","before_hash":"sha256:null","caveats":["Manual findings require evidence review before scientific use."],"id":"vev_2ceb3b3d56d5710d","kind":"finding.asserted","payload":{"proposal_id":"vpr_22c5a651dca0850f"},"reason":"Manual finding added to frontier state","schema":"vela.event.v0.1","signature":"de17942fcebbac9f022be6382c0b1314395c4abf609755d6a15cb925ed38b6f02842c2ddf9545438b0a4b427549523dd32a916c4d97935cb74217d867cd0cb06","target":{"id":"vf_47cdd5e5bf246fe0","type":"finding"},"timestamp":"2026-05-06T03:57:48.653897+00:00"},{"actor":{"id":"reviewer:will-blair-bot","type":"human"},"after_hash":"sha256:e26b00bcdd447e55ee384b6d85fb4a4168ccd0cdcb37d120e5d4e861438637e1","before_hash":"sha256:null","caveats":["Manual findings require evidence review before scientific use."],"id":"vev_2d38e9983324b111","kind":"finding.asserted","payload":{"proposal_id":"vpr_99cb48432035a148"},"reason":"Manual finding added to frontier state","schema":"vela.event.v0.1","signature":"e676eab1bfe0fa371b5a46a8b0fbb844f73a13c7bf2ca01d49b32ce04a9b57e0cf147a78873531fefc85586a2cf2e6d4e67f48c23e2856ea66adffe81aab3901","target":{"id":"vf_492d3cfa2c3df2cd","type":"finding"},"timestamp":"2026-05-06T03:57:47.371409+00:00"},{"actor":{"id":"reviewer:will-blair-bot","type":"human"},"after_hash":"sha256:932842df2f6883671c28b704c70ae3f0e131dfaa7ecbdd06a2418ac2f109c475","before_hash":"sha256:null","caveats":["Manual findings require evidence review before scientific use."],"id":"vev_2d600dd2c6d8a3c8","kind":"finding.asserted","payload":{"proposal_id":"vpr_d01beb316786f3bd"},"reason":"Manual finding added to frontier state","schema":"vela.event.v0.1","signature":"bbb9d564606848500cfac35fc981d7d6741cc6440b2603f770034d06c5629243bc37a33df3d373ed7bb299943cd9fa974a54d45ea32c6e1c7055676d38eaf903","target":{"id":"vf_08c81dd507f6a047","type":"finding"},"timestamp":"2026-05-06T03:57:47.744193+00:00"},{"actor":{"id":"reviewer:will-blair-bot","type":"human"},"after_hash":"sha256:88dc0d324214713c9302dae066f839ab0ae67dbb9780a64575e8e80d7fa0400e","before_hash":"sha256:null","caveats":["Manual findings require evidence review before scientific use."],"id":"vev_2f6ced9514ed2df6","kind":"finding.asserted","payload":{"proposal_id":"vpr_9b41ea4d7c163448"},"reason":"Manual finding added to frontier state","schema":"vela.event.v0.1","signature":"9a96b4df63ef77a6d2336b34973a63ad0877373dc7f00fabf3c63223ea254aa764c877d6cf5736a1aeef976aa16e0a8210f7639e57c1b1e12bb7c104ba04ac02","target":{"id":"vf_d42dc785b45dde84","type":"finding"},"timestamp":"2026-05-06T03:57:47.324921+00:00"},{"actor":{"id":"reviewer:will-blair-bot","type":"human"},"after_hash":"sha256:null","before_hash":"sha256:null","caveats":["Source adapter output is registry metadata, not a clinical conclusion.","Truth-changing frontier updates require reviewer acceptance."],"id":"vev_309b4b9f630f813f","kind":"artifact.asserted","payload":{"artifact":{"access_tier":"public","content_hash":"sha256:bdcdc22b4fc67a5ba764acbb3d745ee0de3a7787c7a9dfaf41e1beb922fed173","created":"2026-05-06T19:41:57.617706+00:00","id":"va_c8941a3227e50131","kind":"clinical_trial_record","license":"public source locator; no restricted bytes deposited","locator":"https://clinicaltrials.gov/study/NCT01739348","media_type":"application/json","metadata":{"adapter":"clinicaltrials-gov-v2","api_url":"https://clinicaltrials.gov/api/v2/studies/NCT01739348","artifact_packet_id":"cap_818a078e8b9d8ed6","entry_id":"ct-verubecestat-mild-moderate","external_artifact_id":"clinicaltrials_gov_v2_NCT01739348","nct_id":"NCT01739348","new_content_hash":"sha256:bdcdc22b4fc67a5ba764acbb3d745ee0de3a7787c7a9dfaf41e1beb922fed173","old_artifact_id":"va_152658b90b27b99e","old_content_hash":"sha256:656ddbd776827df0110a6882d8d3d5f1f4fe33aafa3801fa89930656adec1636","parent_artifact_ids":["sir_68a1577de35d0d91_manifest"],"producer_agent":"adapter:clinicaltrials-gov-v2","retrieved_at":"2026-05-06T19:41:56.546984+00:00","run_id":"sir_68a1577de35d0d91","source_url":"https://clinicaltrials.gov/study/NCT01739348","target_findings":["vf_61168d24f5a8aa3c"],"topic":"Anti-amyloid translation in Alzheimer's disease"},"name":"ClinicalTrials.gov NCT01739348 · An Efficacy and Safety Trial of Verubecestat (MK-8931) in Mild to Moderate Alzheimer's Disease (P07738)","provenance":{"authors":[{"name":"ClinicalTrials.gov API v2 source adapter","orcid":null}],"citation_count":null,"doi":null,"extraction":{"extracted_at":"2026-05-06T19:41:57.617668+00:00","extractor_version":"vela/0.55.0","method":"artifact_to_state_import","model":"adapter:clinicaltrials-gov-v2","model_version":null},"journal":null,"openalex_id":null,"pmc":null,"pmid":null,"publisher":"artifact packet","review":{"corrections":[],"reviewed":false,"reviewed_at":null,"reviewer":null},"source_type":"clinical_trial","title":"cap_818a078e8b9d8ed6 · ClinicalTrials.gov NCT01739348 · An Efficacy and Safety Trial of Verubecestat (MK-8931) in Mild to Moderate Alzheimer's Disease (P07738)","url":"https://clinicaltrials.gov/study/NCT01739348","year":null},"retracted":false,"source_url":"https://clinicaltrials.gov/study/NCT01739348","storage_mode":"remote","target_findings":["vf_61168d24f5a8aa3c"]},"proposal_id":"vpr_2913d6425eca05ee"},"reason":"Import artifact clinicaltrials_gov_v2_NCT01739348 from artifact packet cap_818a078e8b9d8ed6","schema":"vela.event.v0.1","signature":"7711fc247cacdb0b7ea18f6e4aaa47f442844dbee736d7947ae9931288bb2fb6ae4239b855156c2c524de3d6dd16a4c6dda4682dac74a12ce1e055f7f9d8a307","target":{"id":"va_c8941a3227e50131","type":"artifact"},"timestamp":"2026-05-06T19:41:57.669181+00:00"},{"actor":{"id":"reviewer:will-blair-bot","type":"human"},"after_hash":"sha256:af2bd414ede2f7fcd4903277d37022aa139c45471f296fff1596c3d1d409c5a5","before_hash":"sha256:null","caveats":["Manual findings require evidence review before scientific use."],"id":"vev_310f0a38204e8575","kind":"finding.asserted","payload":{"proposal_id":"vpr_3969c44c787e15e6"},"reason":"Manual finding added to frontier state","schema":"vela.event.v0.1","signature":"cd95c2c851229a8708ff68bbe44900df74bb7c09c98977adc005a8e9c0bdaf0bdab74745cfcd03f8c2210bd7ea338d7ce026cadc36b21612cc7883881c1c1204","target":{"id":"vf_c7f8be49ea6547d8","type":"finding"},"timestamp":"2026-05-06T03:57:51.228814+00:00"},{"actor":{"id":"reviewer:will-blair-bot","type":"human"},"after_hash":"sha256:6dd242e8c420465c44851e34dc787a15e1f39bdb39081993501d6e6cdc33b7ce","before_hash":"sha256:null","caveats":["Manual findings require evidence review before scientific use."],"id":"vev_311f4d3a7162ef75","kind":"finding.asserted","payload":{"proposal_id":"vpr_213966f92cf8436f"},"reason":"Manual finding added to frontier state","schema":"vela.event.v0.1","signature":"5de1dccfd8dd1081911811795af45916e3acc8fbc1e617fb6995739deccfc7d6393470441f561026bba9d3fb562f9f07e20c02266e1623ee257357cce5fa940d","target":{"id":"vf_1b37c93a4f619a86","type":"finding"},"timestamp":"2026-05-06T03:57:48.201837+00:00"},{"actor":{"id":"reviewer:will-blair-bot","type":"human"},"after_hash":"sha256:null","before_hash":"sha256:null","caveats":[],"id":"vev_314b00cac905b485","kind":"artifact.asserted","payload":{"artifact":{"access_tier":"public","content_hash":"sha256:20d28db6a6b6f96eb9cfd5af148dbf913eb6f7903bb8b9e7902771d093c8c9b8","created":"2026-05-06T08:30:00.865399+00:00","id":"va_bc4cfba0442848b1","kind":"dataset","license":"FDA FAERS public dashboard; query manifest only, no patient-level data deposited","locator":".vela/artifact-blobs/sha256/20d28db6a6b6f96eb9cfd5af148dbf913eb6f7903bb8b9e7902771d093c8c9b8","media_type":"application/json","metadata":{"ingest_entry_id":"safety-faers-anti-amyloid-query","repository":"FAERS"},"name":"FAERS anti-amyloid safety surveillance query manifest","provenance":{"authors":[],"citation_count":null,"doi":null,"extraction":{"extracted_at":"2026-05-06T08:30:00.865376+00:00","extractor_version":"0.54.0","method":"artifact_deposit","model":null,"model_version":null},"journal":null,"license":"FDA FAERS public dashboard; query manifest only, no patient-level data deposited","openalex_id":null,"pmc":null,"pmid":null,"review":null,"source_type":"data_release","title":"FAERS public dashboard anti-amyloid query manifest","url":"https://fis.fda.gov/sense/app/95239e26-e0be-42d9-a960-9a5f7f1c25ee/sheet/7a47a261-d58b-4203-a8aa-6d3021737452/state/analysis","year":null},"retracted":false,"size_bytes":1024,"source_url":"https://fis.fda.gov/sense/app/95239e26-e0be-42d9-a960-9a5f7f1c25ee/sheet/7a47a261-d58b-4203-a8aa-6d3021737452/state/analysis","storage_mode":"local_blob","target_findings":["vf_d42dc785b45dde84","vf_3d254efae19793ea"]},"proposal_id":"vpr_5bba9c797e1c9258"},"reason":"artifact deposit","schema":"vela.event.v0.1","signature":"2da32f62bbf9090179b83415f169e3c3153157d3d38c82ab1abf80f0d9a9ce8650705539500358740e6708b256eccb4e83d222e7a0e40444eaa93f6752efff07","target":{"id":"va_bc4cfba0442848b1","type":"artifact"},"timestamp":"2026-05-06T08:30:00.880629+00:00"},{"actor":{"id":"reviewer:will-blair-bot","type":"human"},"after_hash":"sha256:4297229ab06764a3bd4e3edc1d3033775d64c2ee8fb101f3fa715f9f3a23b5a8","before_hash":"sha256:d600b074cc22de86918de0c09ecc7e442f1b8dec7ed4bedcd8cfb3149f554b50","caveats":[],"id":"vev_31801464113209d3","kind":"finding.reviewed","payload":{"proposal_id":"vpr_f07704c845e9e7de","status":"contested"},"reason":"Reviewed as a stage and target-form tension against positive antibody programs.","schema":"vela.event.v0.1","signature":"f08b81ff7bc96b7a062a50ffa07129009e3c8c73b2530b893adba7efec509ad88097c38b1e85aa114293ab5629f0b130b9c5a59acd013234af29b363d7301601","target":{"id":"vf_03aac0ab77ae80e8","type":"finding"},"timestamp":"2026-05-06T03:57:53.919215+00:00"},{"actor":{"id":"reviewer:will-blair-bot","type":"human"},"after_hash":"sha256:d7959b048af99f8b4bf44e3accd5e9bd8fb0d49fac9a2b127a5f68d98edb5c52","before_hash":"sha256:null","caveats":["Manual findings require evidence review before scientific use."],"id":"vev_31f27b8687ec7785","kind":"finding.asserted","payload":{"proposal_id":"vpr_f1dd2d20ad25c592"},"reason":"Manual finding added to frontier state","schema":"vela.event.v0.1","signature":"30e6840c9b2f0967cd28397be080526a456ed8e2fa19d131d009da3d7fd9168674f5861885834742e584d62b107f6613f48664e8e03f19958c8162d5f0ea6b02","target":{"id":"vf_2f5a87e11029cdff","type":"finding"},"timestamp":"2026-05-06T03:57:47.850707+00:00"},{"actor":{"id":"reviewer:will-blair","type":"human"},"after_hash":"sha256:d5ae5a0eff319adb1e7e72ac60ef2195abc627b5de7c15869b95bce22ce73e0a","before_hash":"sha256:cd5165348e22249cece9f18b9c3e161a182186de9efec9ad94504ae41604b618","caveats":[],"id":"vev_32642dcf29862edf","kind":"finding.entity_resolved","payload":{"confidence":0.95,"entity_name":"claudin-5","id":"O95832","matched_name":"CLDN5","proposal_id":"vpr_5d60f1d220d27332","resolution_method":"manual","resolution_provenance":"delegated_human_curation","source":"uniprot"},"reason":"Wave A.2 curation: canonical entity resolution against standard ontologies (UniProt for proteins, MeSH for cell types and anatomical structures). All identifiers are unambiguous standard mappings.","schema":"vela.event.v0.1","target":{"id":"vf_155dd090fb7c6ff7","type":"finding"},"timestamp":"2026-05-10T00:21:35.557347+00:00"},{"actor":{"id":"reviewer:will-blair-bot","type":"human"},"after_hash":"sha256:a098c6bc6bc5ebbeeff7a743aacec97b37af380f20279300e9015fd47c1a88a0","before_hash":"sha256:null","caveats":["Manual findings require evidence review before scientific use."],"id":"vev_327adee886e476e1","kind":"finding.asserted","payload":{"proposal_id":"vpr_fb13d9c46980221c"},"reason":"Manual finding added to frontier state","schema":"vela.event.v0.1","signature":"7db9cbc21afb7be0083b42b3bd5e1739155b0f840cab9ddb21e1c7d9ccd4dc75523f052ec8c9199fe2f60e3e1b876a6d58d1e79d525761e87ae618e76813b806","target":{"id":"vf_b299e3ad7965e4d7","type":"finding"},"timestamp":"2026-05-06T03:57:51.746617+00:00"},{"actor":{"id":"reviewer:will-blair-bot","type":"human"},"after_hash":"sha256:702269be6462e7ae62ae078d3252e938888aaf575d92d4edf35f2c86b1de905e","before_hash":"sha256:null","caveats":["Manual findings require evidence review before scientific use."],"id":"vev_346812b8fb7f07e8","kind":"finding.asserted","payload":{"proposal_id":"vpr_9e8421af35d93d1e"},"reason":"Manual finding added to frontier state","schema":"vela.event.v0.1","signature":"8609edf0ae358d7a449aafa24088d5e9317cfb11e7f3d8240a686a00374162557440c54115d5fb3dc7cd4aa363fcd1272dad638f3fe4e37eca73ce66ed7c4a0d","target":{"id":"vf_ce83dfe6fbe4c01d","type":"finding"},"timestamp":"2026-05-06T03:57:47.356187+00:00"},{"actor":{"id":"reviewer:will-blair-bot","type":"human"},"after_hash":"sha256:null","before_hash":"sha256:null","caveats":[],"id":"vev_34c3b16dd1af96df","kind":"artifact.asserted","payload":{"artifact":{"access_tier":"public","content_hash":"sha256:dfb25c8303c6884dd2f47e9bab2c8cc29965993b3772af55aa1ea33589be08f7","created":"2026-05-06T03:57:57.786147+00:00","id":"va_c5e7c3b254fd9c83","kind":"registry_record","license":"Public locator manifest; source access terms apply","locator":".vela/artifact-blobs/sha256/dfb25c8303c6884dd2f47e9bab2c8cc29965993b3772af55aa1ea33589be08f7","media_type":"application/json","metadata":{"agency":"FDA","drug":"aducanumab"},"name":"Aduhelm FDA information page","provenance":{"authors":[],"citation_count":null,"doi":null,"extraction":{"extracted_at":"2026-05-06T03:57:57.786132+00:00","extractor_version":"0.54.0","method":"artifact_deposit","model":null,"model_version":null},"journal":null,"license":"Public locator manifest; source access terms apply","openalex_id":null,"pmc":null,"pmid":null,"review":null,"source_type":"database_record","title":"FDA Aduhelm information","url":"https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/aduhelm-aducanumab-avwa-information","year":null},"retracted":false,"size_bytes":498,"source_url":"https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/aduhelm-aducanumab-avwa-information","storage_mode":"local_blob","target_findings":["vf_4d8aa40cc734ab93"]},"proposal_id":"vpr_1d8a1e188729eca6"},"reason":"public regulatory or dataset locator manifest","schema":"vela.event.v0.1","signature":"7719bcc16b45ef7820c307b24d7ce55eba6428b17a248c11afd41c72171d2e8487b9ce866925e2caef54cef6f2a15618011ac62f25b7f258772c086004e1df0a","target":{"id":"va_c5e7c3b254fd9c83","type":"artifact"},"timestamp":"2026-05-06T03:57:57.798169+00:00"},{"actor":{"id":"reviewer:will-blair-bot","type":"human"},"after_hash":"sha256:eb97a3fd1f4a43ed54c7da794402fe8c2bbbfcd86308c62c832a867e24b86f76","before_hash":"sha256:330d792572930f6cc42f47c1e880c8509ff2d616133699d7188ca7bb3e3eb991","caveats":[],"id":"vev_35103f7f0b3d0dce","kind":"finding.reviewed","payload":{"proposal_id":"vpr_4c253b0b824aafb2","status":"needs_revision"},"reason":"Very small human sample; delivery signal should not be generalized.","schema":"vela.event.v0.1","signature":"f3e34599dba47db85d639b3b5647ae6231bb7b03d1e19a92febfb5354b4e13fc72dec390cd2fba6a75e8a012a81102cf66cef8323e8ccb8dda61c8f6f197f80c","target":{"id":"vf_56f893a9fe9651de","type":"finding"},"timestamp":"2026-05-06T03:57:53.807979+00:00"},{"actor":{"id":"reviewer:will-blair-bot","type":"human"},"after_hash":"sha256:eee0d72712d5192a51d6cafc2006828d94385285ba5269ece199730e5c141504","before_hash":"sha256:null","caveats":["Manual findings require evidence review before scientific use."],"id":"vev_35e4802708d37414","kind":"finding.asserted","payload":{"proposal_id":"vpr_986fcbec9db12008"},"reason":"Manual finding added to frontier state","schema":"vela.event.v0.1","signature":"fdb93f5b4040a239b409345c2ea05cf4a6bdc48cf3cb723eae1b3d29f8c6fb54748311d037c23a2b56f53e4d18ce4d8587fe3cae5430588d2d16d3459dbfd30d","target":{"id":"vf_8bc2689859ba7334","type":"finding"},"timestamp":"2026-05-06T03:57:47.722039+00:00"},{"actor":{"id":"reviewer:will-blair-bot","type":"human"},"after_hash":"sha256:null","before_hash":"sha256:null","caveats":[],"id":"vev_36bfee048a515a01","kind":"artifact.asserted","payload":{"artifact":{"access_tier":"public","content_hash":"sha256:2e2bd5c3c27d68d2c38d30517822794fb37c10a9354f35467c9d153a2420f909","created":"2026-05-06T03:57:54.887289+00:00","id":"va_1b8dad799943d661","kind":"clinical_trial_record","license":"ClinicalTrials.gov public record","locator":".vela/artifact-blobs/sha256/2e2bd5c3c27d68d2c38d30517822794fb37c10a9354f35467c9d153a2420f909","media_type":"application/json","metadata":{"completion_date":"2029-06-30","conditions":["Early Alzheimer's Disease"],"has_results":false,"interventions":["Lecanemab IV","Placebo","Lecanemab SC"],"nct_id":"NCT03887455","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_outcomes":["Core Study: Change from Baseline in the CDR-SB at 18 Months","Extension Phase: Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs)","Extension Phase: Change from Core Study Baseline in CDR-SB","Extension Phase Part B: Number of Participants Exposed to Lecanemab"],"retrieved_at":"2026-05-06T03:57:54.887245+00:00","source_api":"clinicaltrials.gov-v2","start_date":"2019-03-27"},"name":"A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease","provenance":{"authors":[],"citation_count":null,"doi":null,"extraction":{"extracted_at":"2026-05-06T03:57:54.887261+00:00","extractor_version":"0.54.0","method":"artifact_deposit","model":null,"model_version":null},"journal":null,"license":"ClinicalTrials.gov public record","openalex_id":null,"pmc":null,"pmid":null,"review":null,"source_type":"clinical_trial","title":"A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease","url":"https://clinicaltrials.gov/study/NCT03887455","year":null},"retracted":false,"size_bytes":63395,"source_url":"https://clinicaltrials.gov/study/NCT03887455","storage_mode":"local_blob","target_findings":["vf_9ded3333a52f3e58"]},"proposal_id":"vpr_63704441d75c6689"},"reason":"public trial record for anti-amyloid frontier (NCT03887455)","schema":"vela.event.v0.1","signature":"5402eb73209271642569a14fd7ff505907d086a10bb570738c692de38e89fac29dd6bb452e857d4ebc498296a65ab79208b1462fe70484b31b04e592c1ac4b02","target":{"id":"va_1b8dad799943d661","type":"artifact"},"timestamp":"2026-05-06T03:57:54.899507+00:00"},{"actor":{"id":"reviewer:will-blair-bot","type":"human"},"after_hash":"sha256:null","before_hash":"sha256:null","caveats":[],"id":"vev_3788171cd040baac","kind":"artifact.asserted","payload":{"artifact":{"access_tier":"public","content_hash":"sha256:2951cbf52cf27ff53ca1993902cf274ddaa27ab973c395dbfc7f8ae0060436d4","created":"2026-05-06T05:20:47.702166+00:00","id":"va_c1432bb0eb48098a","kind":"table","license":"CC0-1.0; derived Vela review artifact","locator":".vela/artifact-blobs/sha256/2951cbf52cf27ff53ca1993902cf274ddaa27ab973c395dbfc7f8ae0060436d4","media_type":"application/json","metadata":{"schema":"vela.trial-outcomes.v1"},"name":"Anti-amyloid trial outcomes v1","provenance":{"authors":[],"citation_count":null,"doi":null,"extraction":{"extracted_at":"2026-05-06T05:20:47.702082+00:00","extractor_version":"0.54.0","method":"artifact_deposit","model":null,"model_version":null},"journal":null,"license":"CC0-1.0; derived Vela review artifact","openalex_id":null,"pmc":null,"pmid":null,"review":null,"source_type":"database_record","title":"Anti-amyloid trial outcomes v1","url":"https://vela-site.fly.dev/workbench?vfr=vfr_5076e7b3ff8e6b0f","year":null},"retracted":false,"size_bytes":13075,"source_url":"https://vela-site.fly.dev/workbench?vfr=vfr_5076e7b3ff8e6b0f","storage_mode":"local_blob","target_findings":["vf_9ded3333a52f3e58","vf_7b4bfdf919b22af5","vf_03875dbe6be66b00"]},"proposal_id":"vpr_265d8a6400b83ace"},"reason":"trial outcome projection","schema":"vela.event.v0.1","signature":"c52e322a0271f971972d22b34bb6fcbb7437927ef15a6570e0b947721cabd8e18a156f70e6049a1898556e52af3bda84c6c43d290e79e48715a641ebc0545d02","target":{"id":"va_c1432bb0eb48098a","type":"artifact"},"timestamp":"2026-05-06T05:20:47.743593+00:00"},{"actor":{"id":"reviewer:will-blair-bot","type":"human"},"after_hash":"sha256:c9d9ea6d56a28fa7529a19009251717a16d9e20e65a26c7fae8692c484100f4e","before_hash":"sha256:null","caveats":["Manual findings require evidence review before scientific use."],"id":"vev_378b41e77457943b","kind":"finding.asserted","payload":{"proposal_id":"vpr_396b5b07382da500"},"reason":"Manual finding added to frontier state","schema":"vela.event.v0.1","signature":"1bddd1d8b4e9160d907101daa9243e37f48e56f1626459cc7dda177b1b6533cbff1ccfb5167df41d57f4a6dbdb8b8623ec054e14a447012080da2d358c0f910a","target":{"id":"vf_9a4c5010e77212f3","type":"finding"},"timestamp":"2026-05-06T03:57:48.685754+00:00"},{"actor":{"id":"reviewer:will-blair","type":"human"},"after_hash":"sha256:02a4be3c2d48e7e7002a57602c386045956166cdc0852a3efa757179b87504d8","before_hash":"sha256:98409ab69e3dd19534a4417d61015b960efb492d5546b9006b82f7547381838b","caveats":[],"id":"vev_37c6ac65d30ce3b4","kind":"finding.entity_resolved","payload":{"confidence":0.95,"entity_name":"blood-brain barrier","id":"D001812","matched_name":"Blood-Brain Barrier","proposal_id":"vpr_89fb94bdd3aee792","resolution_method":"manual","resolution_provenance":"delegated_human_curation","source":"mesh"},"reason":"Wave A.2 curation: canonical entity resolution against standard ontologies (UniProt for proteins, MeSH for cell types and anatomical structures). All identifiers are unambiguous standard mappings.","schema":"vela.event.v0.1","target":{"id":"vf_155dd090fb7c6ff7","type":"finding"},"timestamp":"2026-05-10T00:21:36.588858+00:00"},{"actor":{"id":"reviewer:will-blair","type":"human"},"after_hash":"sha256:4dc0bcf298e4db59e596fc765301454f71d425c209b525056efa5c120650db6d","before_hash":"sha256:c892d9604a1480956a462f3c3732a070310fbe6f5ea353de56d8254eb8472240","caveats":[],"id":"vev_3847f3f3ddfaeb4d","kind":"finding.span_repaired","payload":{"proposal_id":"vpr_ac0f8badc71a5eef","section":"Bartels 2010 abstract / van Assema 2012 review","text":"P-glycoprotein expression and function at the blood-brain barrier decreases with age and is further reduced in Alzheimer's disease patients, as measured by [11C]-verapamil PET. Reduced P-glycoprotein efflux contributes to cerebral amyloid-beta accumulation. The same transporter limits CNS penetration of multiple oncology drugs at the glioblastoma infiltrative margin."},"reason":"Wave A.3 curation: paraphrased span anchored to Bartels et al. Neurobiol Aging 2010 (age-related P-gp decline) and van Assema et al. Brain 2012 (P-gp dysfunction in AD review). Span is curator-paraphrased; cited paper sections are the load-bearing ones.","schema":"vela.event.v0.1","target":{"id":"vf_5142fb9694998132","type":"finding"},"timestamp":"2026-05-10T00:22:03.071969+00:00"},{"actor":{"id":"reviewer:will-blair","type":"human"},"after_hash":"sha256:92450dd3dd392be7e23e3d4648fef1143ad43adfe2917d877e145379d3c586cb","before_hash":"sha256:f76a7067fa0628bfa4c5b47f9fa285299b8c7ac9fb892399eb3c458fcdf8fb8d","caveats":[],"id":"vev_39ee5ceddd880efc","kind":"finding.entity_resolved","payload":{"confidence":0.92,"entity_name":"amyloid-beta","id":"P05067","matched_name":"APP (amyloid precursor)","proposal_id":"vpr_53876d5d4438345c","resolution_method":"manual","resolution_provenance":"delegated_human_curation","source":"uniprot"},"reason":"Wave A.2 curation: canonical entity resolution against standard ontologies (UniProt for proteins, MeSH for cell types and anatomical structures). All identifiers are unambiguous standard mappings. Amyloid-beta is the cleavage product of APP; the UniProt entry P05067 is the canonical anchor for the parent protein and the standard reference for amyloid-beta peptide research.","schema":"vela.event.v0.1","target":{"id":"vf_5142fb9694998132","type":"finding"},"timestamp":"2026-05-10T00:21:37.676149+00:00"},{"actor":{"id":"reviewer:will-blair-bot","type":"human"},"after_hash":"sha256:f5c257bb321638a0978aa0ad72c64011307ffdbb9873db21ef1deffb1528872c","before_hash":"sha256:null","caveats":["Manual findings require evidence review before scientific use."],"id":"vev_3b8c38059441610f","kind":"finding.asserted","payload":{"proposal_id":"vpr_8114b0e17e92a084"},"reason":"Manual finding added to frontier state","schema":"vela.event.v0.1","signature":"596c40ce8008b51c9021662dfae6fcd83e2d492535842eeee92e46a55b0e8af7753d4c82ae7ad837566d9cb06a793e868aba241b4156739209195e44ec895d0d","target":{"id":"vf_672632084731817f","type":"finding"},"timestamp":"2026-05-06T03:57:49.274987+00:00"},{"actor":{"id":"reviewer:will-blair-bot","type":"human"},"after_hash":"sha256:4e0aa5692d31f63721ed6e60c0ec53c49e5c38ce0da877bcfd8a0764fdbc254a","before_hash":"sha256:null","caveats":["Manual findings require evidence review before scientific use."],"id":"vev_3f4acc2a773816a8","kind":"finding.asserted","payload":{"proposal_id":"vpr_4a8226dd86ebd82b"},"reason":"Manual finding added to frontier state","schema":"vela.event.v0.1","signature":"fa73ee9076d0249380895a01282936c54a19089af432be26b0da1744f2fb17dd760fc65ad6ed9150a0f496a7ddcd76049c901cf6055b52fea1bee6f62d1fed04","target":{"id":"vf_d35b8235e5093334","type":"finding"},"timestamp":"2026-05-06T03:57:48.376805+00:00"},{"actor":{"id":"reviewer:will-blair-bot","type":"human"},"after_hash":"sha256:5889afb24011dc75bb56ad84ab42d203e1ca602502957fb7678405f312572c8e","before_hash":"sha256:null","caveats":["Manual findings require evidence review before scientific use."],"id":"vev_3f8cb637a52fca0d","kind":"finding.asserted","payload":{"proposal_id":"vpr_0c0f2d7e59449cda"},"reason":"Manual finding added to frontier state","schema":"vela.event.v0.1","signature":"9cd1102e88b9d5e7bb4bb7fb4fa6893d5e4aa291e4c77bef847d48fa68a8eaa267acfd1e714aa770f7b19ddfb0f736082624e3ef0bf9d1434c58eac424830305","target":{"id":"vf_624f7ed44a262689","type":"finding"},"timestamp":"2026-05-06T03:57:50.311764+00:00"},{"actor":{"id":"reviewer:will-blair-bot","type":"human"},"after_hash":"sha256:null","before_hash":"sha256:null","caveats":["Source adapter output is registry metadata, not a clinical conclusion.","Truth-changing frontier updates require reviewer acceptance."],"id":"vev_40190385aa6da5a2","kind":"artifact.asserted","payload":{"artifact":{"access_tier":"public","content_hash":"sha256:5ce419eca69ee5c69dd8e3d1cbd1a289783683875649e5e79d57a3047da37b9c","created":"2026-05-06T19:41:57.793768+00:00","id":"va_a6590d0640aa9b74","kind":"clinical_trial_record","license":"public source locator; no restricted bytes deposited","locator":"https://clinicaltrials.gov/study/NCT01953601","media_type":"application/json","metadata":{"adapter":"clinicaltrials-gov-v2","api_url":"https://clinicaltrials.gov/api/v2/studies/NCT01953601","artifact_packet_id":"cap_818a078e8b9d8ed6","entry_id":"ct-verubecestat-prodromal","external_artifact_id":"clinicaltrials_gov_v2_NCT01953601","nct_id":"NCT01953601","new_content_hash":"sha256:5ce419eca69ee5c69dd8e3d1cbd1a289783683875649e5e79d57a3047da37b9c","old_artifact_id":"va_4f9a1656fdcd89fb","old_content_hash":"sha256:a570ad1cd3c79fb3788d127b96eca2ab57c0985b72ffe815100f8f412853ad56","parent_artifact_ids":["sir_68a1577de35d0d91_manifest"],"producer_agent":"adapter:clinicaltrials-gov-v2","retrieved_at":"2026-05-06T19:41:56.546984+00:00","run_id":"sir_68a1577de35d0d91","source_url":"https://clinicaltrials.gov/study/NCT01953601","target_findings":["vf_61168d24f5a8aa3c"],"topic":"Anti-amyloid translation in Alzheimer's disease"},"name":"ClinicalTrials.gov NCT01953601 · Efficacy and Safety Trial of Verubecestat (MK-8931) in Participants With Prodromal Alzheimer's Disease (MK-8931-019)","provenance":{"authors":[{"name":"ClinicalTrials.gov API v2 source adapter","orcid":null}],"citation_count":null,"doi":null,"extraction":{"extracted_at":"2026-05-06T19:41:57.793725+00:00","extractor_version":"vela/0.55.0","method":"artifact_to_state_import","model":"adapter:clinicaltrials-gov-v2","model_version":null},"journal":null,"openalex_id":null,"pmc":null,"pmid":null,"publisher":"artifact packet","review":{"corrections":[],"reviewed":false,"reviewed_at":null,"reviewer":null},"source_type":"clinical_trial","title":"cap_818a078e8b9d8ed6 · ClinicalTrials.gov NCT01953601 · Efficacy and Safety Trial of Verubecestat (MK-8931) in Participants With Prodromal Alzheimer's Disease (MK-8931-019)","url":"https://clinicaltrials.gov/study/NCT01953601","year":null},"retracted":false,"source_url":"https://clinicaltrials.gov/study/NCT01953601","storage_mode":"remote","target_findings":["vf_61168d24f5a8aa3c"]},"proposal_id":"vpr_cf33103a58ad222c"},"reason":"Import artifact clinicaltrials_gov_v2_NCT01953601 from artifact packet cap_818a078e8b9d8ed6","schema":"vela.event.v0.1","signature":"fb589b28ecd46f5cf2773d5dca687e0608892dbc4ec270713c3fde9d7779623e9db679f0d8ebcf57d2e0b8e5e43f1852a031be19e8b8d89896943edc16d43d04","target":{"id":"va_a6590d0640aa9b74","type":"artifact"},"timestamp":"2026-05-06T19:41:57.849635+00:00"},{"actor":{"id":"reviewer:will-blair-bot","type":"human"},"after_hash":"sha256:3ee7b06a21613d7bdea8652db6133e055280394d5219e0f8e621b0160b6d3367","before_hash":"sha256:null","caveats":["Manual findings require evidence review before scientific use."],"id":"vev_401ee4c15a6dc2a4","kind":"finding.asserted","payload":{"proposal_id":"vpr_ebec765bdd0348ba"},"reason":"Manual finding added to frontier state","schema":"vela.event.v0.1","signature":"2dcfc8b57f08341a52a426adc3a755550ab4f7928195acf8e4672ddfd3ab40fc2ac4d7b5ce684e69d2717928d10f7d9c951215ad5ab8bc438d163afedc9f6b08","target":{"id":"vf_61168d24f5a8aa3c","type":"finding"},"timestamp":"2026-05-06T03:57:50.777976+00:00"},{"actor":{"id":"reviewer:will-blair-bot","type":"human"},"after_hash":"sha256:3b74d7a15df05ff82fb977cfe91e9774efbdcea405da8c3b17cfbce72cfeb14f","before_hash":"sha256:c96f1b3bc38f10ea5e43044b7eeb925426e456ac8c5d531eaf7b1d8a408d29ee","caveats":[],"id":"vev_40f375196c00dc63","kind":"finding.reviewed","payload":{"proposal_id":"vpr_5e921e957ea492cb","status":"accepted"},"reason":"Accepted as a broad-frontier seed inside the anti-amyloid scope; source locator remains the authority.","schema":"vela.event.v0.1","signature":"cbe4ecd646e75cd42de98b6a5f2cfb61d1814108a631ab58dca6a0869bb978e268b9a65d41552404fe9fd5fd1357c99c5f13469d9474479740c53eb149f8c400","target":{"id":"vf_c8bc589dc291ef29","type":"finding"},"timestamp":"2026-05-06T03:57:47.700059+00:00"},{"actor":{"id":"reviewer:will-blair-bot","type":"human"},"after_hash":"sha256:11df29001b1ed3d2c04aa2176ab029979e935e6577421ffd6bb2e16fc2d00ea4","before_hash":"sha256:8ef426efb9ef7bc208640b23e4603567c2c8b72e0f10348793ecc12e4e62b5a4","caveats":["Regulatory source metadata changed; this is a review task, not a claim update.","Accepting this note records reviewer awareness only."],"id":"vev_44f1a5f04c58fcf8","kind":"finding.noted","payload":{"annotation_id":"ann_3bb5e054cc6aa2da","proposal_id":"vpr_1d0faeb172ca1b81","text":"Regulatory source reg-fda-aducanumab changed tracked source fields: source locator changed from https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/aduhelm-aducanumab-avwa-information to https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/aducanumab-marketed-aduhelm-information. Review whether this affects the linked finding scope, trial table, or decision brief; source metadata alone does not change the claim."},"reason":"Regulatory source reg-fda-aducanumab changed tracked source fields: source locator changed from https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/aduhelm-aducanumab-avwa-information to https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/aducanumab-marketed-aduhelm-information. Review whether this affects the linked finding scope, trial table, or decision brief; source metadata alone does not change the claim.","schema":"vela.event.v0.1","signature":"264c08dba4a6eaaf0a68f381f934eab66c22d5601b82bfbbd2750b031a2c6296c077a8519cfa0ad34aeb7b1f4459bf54e7f8e844f37869bb28dd2751b916f506","target":{"id":"vf_4d8aa40cc734ab93","type":"finding"},"timestamp":"2026-05-06T21:06:41.963884+00:00"},{"actor":{"id":"reviewer:will-blair-bot","type":"human"},"after_hash":"sha256:89bc2e61ab69c99889c842d60c12332d136ab88e40051e3435a5230a8b0b7d09","before_hash":"sha256:null","caveats":["Manual findings require evidence review before scientific use."],"id":"vev_45937a0a96aeb3a1","kind":"finding.asserted","payload":{"proposal_id":"vpr_7ad483428aa6f4fc"},"reason":"Manual finding added to frontier state","schema":"vela.event.v0.1","signature":"ad4361d46c9d2438ce6b464aa210371b38724978f11cfe96e535065f3d9f23560ebea655a5a67937cf97c65963868032231c3d02f0c1a71ccd409af0d56b340f","target":{"id":"vf_dfadec272ade726c","type":"finding"},"timestamp":"2026-05-06T03:57:50.178921+00:00"},{"actor":{"id":"reviewer:will-blair-bot","type":"human"},"after_hash":"sha256:340070ed1d1cfb1a501da1fe22d18e7cf5600bbec8aaa828ebd38b12f2ed7829","before_hash":"sha256:null","caveats":["Manual findings require evidence review before scientific use."],"id":"vev_45ac324b56ecd227","kind":"finding.asserted","payload":{"proposal_id":"vpr_5ba6564481b03de7"},"reason":"Manual finding added to frontier state","schema":"vela.event.v0.1","signature":"2add16f5338cbab46133b38b67fa092afce663e254e65cf06febed28c18d8af6fa812847a61b4e082fe1742cf2a6e63666118c51a5d39a34eeb750b5edb59a00","target":{"id":"vf_723edf56419950be","type":"finding"},"timestamp":"2026-05-06T03:57:52.515702+00:00"},{"actor":{"id":"reviewer:will-blair-bot","type":"human"},"after_hash":"sha256:null","before_hash":"sha256:null","caveats":[],"id":"vev_45fd53e6ea3b0419","kind":"artifact.asserted","payload":{"artifact":{"access_tier":"public","content_hash":"sha256:32e5927747f94142f7cab26682e283d77c8036118f8e60307c490ec2125e07d8","created":"2026-05-06T07:19:33.953836+00:00","id":"va_5fd2846d4d546490","kind":"registry_record","license":"public locator; source materials retain EMA terms","locator":".vela/artifact-blobs/sha256/32e5927747f94142f7cab26682e283d77c8036118f8e60307c490ec2125e07d8","media_type":"application/json","metadata":{"agency":"EMA","drug":"lecanemab"},"name":"Leqembi EPAR and EU risk minimisation materials","provenance":{"authors":[],"citation_count":null,"doi":null,"extraction":{"extracted_at":"2026-05-06T07:19:33.953818+00:00","extractor_version":"0.54.0","method":"artifact_deposit","model":null,"model_version":null},"journal":null,"license":"public locator; source materials retain EMA terms","openalex_id":null,"pmc":null,"pmid":null,"review":null,"source_type":"database_record","title":"European Medicines Agency EPAR: Leqembi","url":"https://www.ema.europa.eu/en/medicines/human/EPAR/leqembi","year":null},"retracted":false,"size_bytes":524,"source_url":"https://www.ema.europa.eu/en/medicines/human/EPAR/leqembi","storage_mode":"local_blob","target_findings":["vf_421b336a4bf3e428"]},"proposal_id":"vpr_c28009d4570332a7"},"reason":"EU regulatory locator deposit","schema":"vela.event.v0.1","signature":"34a73dedcc7947b6302ac6253bbc47c65e8aeed69bea305de9c3c1d814f441af6fc3085756e894d3d39757a223fab8d4431013e39750b741e4ba58417e243d0d","target":{"id":"va_5fd2846d4d546490","type":"artifact"},"timestamp":"2026-05-06T07:19:33.971547+00:00"},{"actor":{"id":"reviewer:will-blair-bot","type":"human"},"after_hash":"sha256:f74136dacd80ce500c8a6b5926cbac3f298b45f85c84a731d716004c61d0a002","before_hash":"sha256:2508f0aa09a5736e14ba86f70ce3d368751d01312b0bc097708f9fdcf7a43f90","caveats":[],"id":"vev_47654dede60d19eb","kind":"finding.reviewed","payload":{"proposal_id":"vpr_9fbb9031837f58c3","status":"accepted"},"reason":"Accepted as a broad-frontier seed inside the anti-amyloid scope; source locator remains the authority.","schema":"vela.event.v0.1","signature":"83a9a4a9a04fb1d04726c275d8b7eb71d546950d4bf0f79fa629113b45b88c4a6a0ae09d6dc34061b91bd6cbdffaa2122083ffacecedc409e690f07c8ccef80d","target":{"id":"vf_dc28e2c8084e9f8d","type":"finding"},"timestamp":"2026-05-06T03:57:51.588325+00:00"},{"actor":{"id":"reviewer:will-blair-bot","type":"human"},"after_hash":"sha256:null","before_hash":"sha256:null","caveats":[],"id":"vev_490ec3fac263fc4b","kind":"artifact.asserted","payload":{"artifact":{"access_tier":"public","content_hash":"sha256:181c1d0eb4d1e2eb1ad264d5b7441e7e7011b38007c8ce2c260bf496e68d74d3","created":"2026-05-06T03:57:57.735200+00:00","id":"va_043e75bba50e253e","kind":"registry_record","license":"Public locator manifest; source access terms apply","locator":".vela/artifact-blobs/sha256/181c1d0eb4d1e2eb1ad264d5b7441e7e7011b38007c8ce2c260bf496e68d74d3","media_type":"application/json","metadata":{"agency":"FDA","drug":"donanemab"},"name":"KISUNLA prescribing information and FDA materials","provenance":{"authors":[],"citation_count":null,"doi":null,"extraction":{"extracted_at":"2026-05-06T03:57:57.735187+00:00","extractor_version":"0.54.0","method":"artifact_deposit","model":null,"model_version":null},"journal":null,"license":"Public locator manifest; source access terms apply","openalex_id":null,"pmc":null,"pmid":null,"review":null,"source_type":"database_record","title":"FDA Drugs@FDA: Kisunla","url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761248","year":null},"retracted":false,"size_bytes":492,"source_url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761248","storage_mode":"local_blob","target_findings":["vf_7b4bfdf919b22af5"]},"proposal_id":"vpr_39e414feee65fac7"},"reason":"public regulatory or dataset locator manifest","schema":"vela.event.v0.1","signature":"000520f14ada6fbe43688e7603b563453f7d9bca5690db9c3f324c1dc17bfa9c21f8b8c6c177905155acfab77e9957eab8a9d7122b87a19b58c9343fed36c802","target":{"id":"va_043e75bba50e253e","type":"artifact"},"timestamp":"2026-05-06T03:57:57.746682+00:00"},{"actor":{"id":"reviewer:will-blair-bot","type":"human"},"after_hash":"sha256:e603dafc65b828b34e287d9dd35082b3222ac72b48ad0a47751df423064fb4fe","before_hash":"sha256:null","caveats":["Manual findings require evidence review before scientific use."],"id":"vev_4986354f3db0344c","kind":"finding.asserted","payload":{"proposal_id":"vpr_304c4fa4eb4a44e0"},"reason":"Manual finding added to frontier state","schema":"vela.event.v0.1","signature":"aadef984445aa8c8896e05364024ccdcb9ff3c39bb22b65edd3517dee6cf59b03bc64d03ff3a3aa0ff185d1efb151b6ba4de04e0dc2c9885f02229a3aba7fd00","target":{"id":"vf_74496f743b81b0ee","type":"finding"},"timestamp":"2026-05-06T03:57:50.266866+00:00"},{"actor":{"id":"reviewer:will-blair-bot","type":"human"},"after_hash":"sha256:485e5a019f1680feac7040001f726eda7a9ada913d46c1f13c342d0207dee6ba","before_hash":"sha256:67b61c825a047b7b356df379a66a9662255678fa6330f41ef47cb6d6db736bbe","caveats":[],"id":"vev_4a0f9f42ff0cb923","kind":"finding.reviewed","payload":{"proposal_id":"vpr_33aefa0b61c292a0","status":"contested"},"reason":"Reviewed as a class-tension candidate against positive antibody programs.","schema":"vela.event.v0.1","signature":"43226a32ea3749584839d4aa4c667292e421b3b41c9409463bf5ae9f2e1b3046d2dcbbc562943fc41137a915dc84715275b46f3b056de14d2aa92dec8bad470c","target":{"id":"vf_78e8d7300689c72f","type":"finding"},"timestamp":"2026-05-06T03:57:53.863915+00:00"},{"actor":{"id":"reviewer:will-blair-bot","type":"human"},"after_hash":"sha256:null","before_hash":"sha256:null","caveats":[],"id":"vev_4a2c1c18ce653f3e","kind":"artifact.asserted","payload":{"artifact":{"access_tier":"public","content_hash":"sha256:fb2dbaecac29399643bc3720400bd443007198ce0f41a9dd2d38e983e6c69058","created":"2026-05-06T03:57:57.625257+00:00","id":"va_092f517736c040d5","kind":"clinical_trial_record","license":"ClinicalTrials.gov public record","locator":".vela/artifact-blobs/sha256/fb2dbaecac29399643bc3720400bd443007198ce0f41a9dd2d38e983e6c69058","media_type":"application/json","metadata":{"completion_date":"2029-07","conditions":["Mild Cognitive Impairment","Alzheimer Disease 1"],"has_results":false,"interventions":["Aducanumab","Exablate Model 4000 Type 2","Lecanemab"],"nct_id":"NCT05469009","overall_status":"ACTIVE_NOT_RECRUITING","phases":["EARLY_PHASE1"],"primary_outcomes":["Treatment intervention related adverse events","Treatment intervention related serious adverse events"],"retrieved_at":"2026-05-06T03:57:57.625234+00:00","source_api":"clinicaltrials.gov-v2","start_date":"2022-07-14"},"name":"Safety and Feasibility of Exablate Blood-Brain Barrier Disruption for Mild Cognitive Impairment or Mild Alzheimer's Disease Undergoing Standard of Care Monoclonal Antibody (mAb) Therapy","provenance":{"authors":[],"citation_count":null,"doi":null,"extraction":{"extracted_at":"2026-05-06T03:57:57.625249+00:00","extractor_version":"0.54.0","method":"artifact_deposit","model":null,"model_version":null},"journal":null,"license":"ClinicalTrials.gov public record","openalex_id":null,"pmc":null,"pmid":null,"review":null,"source_type":"clinical_trial","title":"Safety and Feasibility of Exablate Blood-Brain Barrier Disruption for Mild Cognitive Impairment or Mild Alzheimer's Disease Undergoing Standard of Care Monoclonal Antibody (mAb) Therapy","url":"https://clinicaltrials.gov/study/NCT05469009","year":null},"retracted":false,"size_bytes":8974,"source_url":"https://clinicaltrials.gov/study/NCT05469009","storage_mode":"local_blob","target_findings":["vf_56f893a9fe9651de"]},"proposal_id":"vpr_d05991ad1796e3db"},"reason":"public trial record for anti-amyloid frontier (NCT05469009)","schema":"vela.event.v0.1","signature":"da5d84efcc119cea01e70741a9846e093615422afb4ff5322d7b302679a9e8e01d299f78c74a47f035c6f4bdb98118dce7f6d9129bcf749516112fae9aeaeb09","target":{"id":"va_092f517736c040d5","type":"artifact"},"timestamp":"2026-05-06T03:57:57.638530+00:00"},{"actor":{"id":"reviewer:will-blair-bot","type":"human"},"after_hash":"sha256:dfd0dccc4481a2e5322230576e6410340673b5d1aff32d2d1dd23c9233d76245","before_hash":"sha256:7a7acb64802250f7ee693fa7955acc6dc1920991b1684025ee70c0e3ee7667dc","caveats":[],"id":"vev_4b632f2e96853ca3","kind":"finding.reviewed","payload":{"proposal_id":"vpr_49e23f5a2b2007ad","status":"accepted"},"reason":"Reviewed for decision-console use: ARIA/APOE4 risk claim is scoped to anti-amyloid antibody monitoring and stratification.","schema":"vela.event.v0.1","signature":"34abcc2dfd181ad4dd1d4602140a0af9bf8b323da5d3bbdb033a8c2948253a87b2cbe92f28190e73c8de03f710779203bb9835ad3a46880dc3c9a3982cdbe901","target":{"id":"vf_2e7192704f1767e4","type":"finding"},"timestamp":"2026-05-06T05:42:49.894445+00:00"},{"actor":{"id":"reviewer:will-blair-bot","type":"human"},"after_hash":"sha256:null","before_hash":"sha256:null","caveats":["Source adapter output is registry metadata, not a clinical conclusion.","Truth-changing frontier updates require reviewer acceptance."],"id":"vev_4be28a9ad8c0083f","kind":"artifact.asserted","payload":{"artifact":{"access_tier":"public","content_hash":"sha256:5991f62feeaf4ca34052412a5082dc69349022352ddbf1fe5c05e1919b0c52cc","created":"2026-05-06T19:41:56.700491+00:00","id":"va_f15234e27be15331","kind":"clinical_trial_record","license":"public source locator; no restricted bytes deposited","locator":"https://clinicaltrials.gov/study/NCT03887455","media_type":"application/json","metadata":{"adapter":"clinicaltrials-gov-v2","api_url":"https://clinicaltrials.gov/api/v2/studies/NCT03887455","artifact_packet_id":"cap_818a078e8b9d8ed6","entry_id":"ct-lecanemab-clarity-ad","external_artifact_id":"clinicaltrials_gov_v2_NCT03887455","nct_id":"NCT03887455","new_content_hash":"sha256:5991f62feeaf4ca34052412a5082dc69349022352ddbf1fe5c05e1919b0c52cc","old_artifact_id":"va_1b8dad799943d661","old_content_hash":"sha256:2e2bd5c3c27d68d2c38d30517822794fb37c10a9354f35467c9d153a2420f909","parent_artifact_ids":["sir_68a1577de35d0d91_manifest"],"producer_agent":"adapter:clinicaltrials-gov-v2","retrieved_at":"2026-05-06T19:41:56.546984+00:00","run_id":"sir_68a1577de35d0d91","source_url":"https://clinicaltrials.gov/study/NCT03887455","target_findings":["vf_9ded3333a52f3e58"],"topic":"Anti-amyloid translation in Alzheimer's disease"},"name":"ClinicalTrials.gov NCT03887455 · A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease","provenance":{"authors":[{"name":"ClinicalTrials.gov API v2 source adapter","orcid":null}],"citation_count":null,"doi":null,"extraction":{"extracted_at":"2026-05-06T19:41:56.700447+00:00","extractor_version":"vela/0.55.0","method":"artifact_to_state_import","model":"adapter:clinicaltrials-gov-v2","model_version":null},"journal":null,"openalex_id":null,"pmc":null,"pmid":null,"publisher":"artifact packet","review":{"corrections":[],"reviewed":false,"reviewed_at":null,"reviewer":null},"source_type":"clinical_trial","title":"cap_818a078e8b9d8ed6 · ClinicalTrials.gov NCT03887455 · A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease","url":"https://clinicaltrials.gov/study/NCT03887455","year":null},"retracted":false,"source_url":"https://clinicaltrials.gov/study/NCT03887455","storage_mode":"remote","target_findings":["vf_9ded3333a52f3e58"]},"proposal_id":"vpr_5feb471888a7db25"},"reason":"Import artifact clinicaltrials_gov_v2_NCT03887455 from artifact packet cap_818a078e8b9d8ed6","schema":"vela.event.v0.1","signature":"c7bd82f37045afbfef70f417c8d3b7f4140badb6b8fa229a35f3b197595dd5e3a84c4945d99edd3ce7196da735f578fbef0a68a5ceefc6dad7159f4a99b07200","target":{"id":"va_f15234e27be15331","type":"artifact"},"timestamp":"2026-05-06T19:41:56.756222+00:00"},{"actor":{"id":"reviewer:will-blair-bot","type":"human"},"after_hash":"sha256:a8bc36c1d7c3a218026275b79c12fd1cdcb769c809d5bb7c63c6ad9110f548cf","before_hash":"sha256:null","caveats":["Manual findings require evidence review before scientific use."],"id":"vev_4c5c5a0be32f03bc","kind":"finding.asserted","payload":{"proposal_id":"vpr_e7b9a755f3ef54f9"},"reason":"Manual finding added to frontier state","schema":"vela.event.v0.1","signature":"4630ceac4efa32975f77e53df38b6f4352334086ba97366580334ef31f4a5f54c6b48d8e7a74530bf78ce4f96ace97f47b0161c5dcde4e05b963b8f78d3b140e","target":{"id":"vf_b6573124f68cc5f0","type":"finding"},"timestamp":"2026-05-06T03:57:48.922953+00:00"},{"actor":{"id":"reviewer:will-blair-bot","type":"human"},"after_hash":"sha256:330d792572930f6cc42f47c1e880c8509ff2d616133699d7188ca7bb3e3eb991","before_hash":"sha256:null","caveats":["Manual findings require evidence review before scientific use."],"id":"vev_4d144ddf5883a140","kind":"finding.asserted","payload":{"proposal_id":"vpr_26b5501c9e58397b"},"reason":"Manual finding added to frontier state","schema":"vela.event.v0.1","signature":"9a518913f59c1c3f927dd2866cc82f621f70e781f3244777e5f5f5a612a1b1c31c2979c4d2f665da351fa361e7737a444ca0b1e8fe4cc07794c1b1455d93940c","target":{"id":"vf_56f893a9fe9651de","type":"finding"},"timestamp":"2026-05-06T03:57:47.308990+00:00"},{"actor":{"id":"reviewer:will-blair-bot","type":"human"},"after_hash":"sha256:61a728d3513c384b97d010a6859725a2018807881a65dcf78c5d32c1cfa94338","before_hash":"sha256:null","caveats":["Manual findings require evidence review before scientific use."],"id":"vev_4d3f02cddc7e7221","kind":"finding.asserted","payload":{"proposal_id":"vpr_da690b1206e41f7f"},"reason":"Manual finding added to frontier state","schema":"vela.event.v0.1","signature":"17b58ad58eeb8eebcb8f72429eaac2d54a8319090e2f68f7be64e552e4c68b7473f2dada82dc94f38a841c3c49585e34162ac5ae2fa2f8bf28cd85b3a8762908","target":{"id":"vf_2b10fee64b9970af","type":"finding"},"timestamp":"2026-05-06T03:57:47.768393+00:00"},{"actor":{"id":"reviewer:will-blair-bot","type":"human"},"after_hash":"sha256:null","before_hash":"sha256:null","caveats":[],"id":"vev_4d9d782d193adee8","kind":"artifact.asserted","payload":{"artifact":{"access_tier":"public","content_hash":"sha256:0bcca52a2c64a71682a6ea0c9a916cfccbcb23cdb50512eedc2e7f0c7c54b4a8","created":"2026-05-06T03:57:55.162276+00:00","id":"va_6f9aec2bf7f2ee37","kind":"clinical_trial_record","license":"ClinicalTrials.gov public record","locator":".vela/artifact-blobs/sha256/0bcca52a2c64a71682a6ea0c9a916cfccbcb23cdb50512eedc2e7f0c7c54b4a8","media_type":"application/json","metadata":{"completion_date":"2027-11","conditions":["Alzheimer Disease"],"has_results":false,"interventions":["Donanemab","Placebo"],"nct_id":"NCT05026866","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_outcomes":["Time to Clinical Progression of Composite Endpoint as Measured by Clinical Dementia Rating (CDR) in the Primary Study Population (Baseline CDR-Global Score [GS 0])"],"retrieved_at":"2026-05-06T03:57:55.162247+00:00","source_api":"clinicaltrials.gov-v2","start_date":"2021-08-27"},"name":"A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)","provenance":{"authors":[],"citation_count":null,"doi":null,"extraction":{"extracted_at":"2026-05-06T03:57:55.162268+00:00","extractor_version":"0.54.0","method":"artifact_deposit","model":null,"model_version":null},"journal":null,"license":"ClinicalTrials.gov public record","openalex_id":null,"pmc":null,"pmid":null,"review":null,"source_type":"clinical_trial","title":"A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)","url":"https://clinicaltrials.gov/study/NCT05026866","year":null},"retracted":false,"size_bytes":48895,"source_url":"https://clinicaltrials.gov/study/NCT05026866","storage_mode":"local_blob","target_findings":["vf_7b4bfdf919b22af5"]},"proposal_id":"vpr_801f0f2b1bda522f"},"reason":"public trial record for anti-amyloid frontier (NCT05026866)","schema":"vela.event.v0.1","signature":"b4e71c9694a6fb1006d9a4edd1b6b33023c3ba9eed1745ea0ba0b39e2b980cee66348bd892b1260e2332346c582ce5a105c0fe7ae4ff7b302d58a105f7cd150b","target":{"id":"va_6f9aec2bf7f2ee37","type":"artifact"},"timestamp":"2026-05-06T03:57:55.176125+00:00"},{"actor":{"id":"reviewer:will-blair-bot","type":"human"},"after_hash":"sha256:1ab41800709940c676efc002f0f2459a205aedbaad2c9dcc6ed4537684b0c01c","before_hash":"sha256:cd8fca2110e77412435292ca5336f0469de9632b74367dcf49b6075cfa5a1400","caveats":[],"id":"vev_4df1760499ef33ff","kind":"finding.reviewed","payload":{"proposal_id":"vpr_25b9922e459f7974","status":"accepted"},"reason":"Accepted as a broad-frontier seed inside the anti-amyloid scope; source locator remains the authority.","schema":"vela.event.v0.1","signature":"4a0527f10d0f7397b9b4a185d8a917be40d2714a6844149aad50ed0ab398f2ae1c07d5b03fa62d64ca40b4314b4c39e1f2e3abb19ab1df589ac73046b8fe7402","target":{"id":"vf_b10935043fb06532","type":"finding"},"timestamp":"2026-05-06T03:57:50.403697+00:00"},{"actor":{"id":"agent:bbb-curation-bot-2026-05-09","type":"human"},"after_hash":"sha256:157921fd89d8f4e37876b1a240362837d1748c907d9ab72de3300bc502367ee7","before_hash":"sha256:null","caveats":["Manual findings require evidence review before scientific use."],"id":"vev_4e09ed3883f8e049","kind":"finding.asserted","payload":{"proposal_id":"vpr_3cd1d4f810329662"},"reason":"Manual finding added to frontier state","schema":"vela.event.v0.1","target":{"id":"vf_5142fb9694998132","type":"finding"},"timestamp":"2026-05-09T21:02:27.402046+00:00"},{"actor":{"id":"reviewer:will-blair-bot","type":"human"},"after_hash":"sha256:4d337c0f923a685bf0da5169b725c0ff05f286ef9112c7c5cd30c1e2e6d7c1a1","before_hash":"sha256:null","caveats":["Manual findings require evidence review before scientific use."],"id":"vev_4f1da193d7812395","kind":"finding.asserted","payload":{"proposal_id":"vpr_6b3b8f311ce880c3"},"reason":"Manual finding added to frontier state","schema":"vela.event.v0.1","signature":"00124ec4463e4021455fd4b75a4e14f7490848d86080c7216cf77f25df6137218905e828c20f1b622c4de3ad57e98dfaf697f308762eaf06bac0be707890e807","target":{"id":"vf_421b336a4bf3e428","type":"finding"},"timestamp":"2026-05-06T03:57:48.144470+00:00"},{"actor":{"id":"agent:vela-curation-bot-2026-05-09","type":"human"},"after_hash":"sha256:2cbedb788de80d82a25461314d404e440486ae83f5666ddef27e3a8bc6527349","before_hash":"sha256:93660ab7accf1fef0bab7a95875f77f8cc30bb1de28de9034c53f62a0bd739c1","caveats":[],"id":"vev_4f1dbc7414c2957b","kind":"finding.reviewed","payload":{"proposal_id":"vpr_fe1facc0dc7a30c2","status":"accepted"},"reason":"TRAILBLAZER-ALZ Phase II (Mintun et al., NEJM 2021) was the foundational signal that donanemab clears amyloid plaques. Agent-drafted accept; eligible for human re-review.","schema":"vela.event.v0.1","target":{"id":"vf_98bca71097f11704","type":"finding"},"timestamp":"2026-05-09T21:33:33.630463+00:00"},{"actor":{"id":"reviewer:will-blair-bot","type":"human"},"after_hash":"sha256:5409e3788261861cc3a135ab49ee0b7f07f6146507b4c946c0ec7cc70adfd48d","before_hash":"sha256:null","caveats":["Manual findings require evidence review before scientific use."],"id":"vev_4fe1d169af71f64f","kind":"finding.asserted","payload":{"proposal_id":"vpr_ad6728f8155d6c0c"},"reason":"Manual finding added to frontier state","schema":"vela.event.v0.1","signature":"db2978558aea26c4a0cf0eb2773d2a67f2ad4a3d885985988d4344e7c8c580124a7cb62534e499a2dc5dce21f80a8919dd1e22eecda87acd054c6b608619db05","target":{"id":"vf_0bcf6cd07682db80","type":"finding"},"timestamp":"2026-05-06T03:57:50.222296+00:00"},{"actor":{"id":"reviewer:will-blair-bot","type":"human"},"after_hash":"sha256:13b236a1096736d730c290d3e1725e1bb9be2bedfe373326e0cd33b2e0d8dcc4","before_hash":"sha256:null","caveats":["Manual findings require evidence review before scientific use."],"id":"vev_4fe46ce0b645b160","kind":"finding.asserted","payload":{"proposal_id":"vpr_ec4108d02b60d3dc"},"reason":"Manual finding added to frontier state","schema":"vela.event.v0.1","signature":"12d017d68631943ef03cc8a1bf873cd03f82cf4d049002b925ba2705f1ccfcdd866993d4ff0080fe62975149fe858b0816efaf1e0c6e2c0d69fbaf7b83ee4400","target":{"id":"vf_1e974fb24f241002","type":"finding"},"timestamp":"2026-05-06T03:57:47.954042+00:00"},{"actor":{"id":"reviewer:will-blair-bot","type":"human"},"after_hash":"sha256:null","before_hash":"sha256:null","caveats":[],"id":"vev_50412918baab20e8","kind":"artifact.asserted","payload":{"artifact":{"access_tier":"public","content_hash":"sha256:a570ad1cd3c79fb3788d127b96eca2ab57c0985b72ffe815100f8f412853ad56","created":"2026-05-06T03:57:55.915673+00:00","id":"va_4f9a1656fdcd89fb","kind":"clinical_trial_record","license":"ClinicalTrials.gov public record","locator":".vela/artifact-blobs/sha256/a570ad1cd3c79fb3788d127b96eca2ab57c0985b72ffe815100f8f412853ad56","media_type":"application/json","metadata":{"completion_date":"2018-04-17","conditions":["Amnestic Mild Cognitive Impairment","Alzheimer's Disease","Prodromal Alzheimer's Disease"],"has_results":true,"interventions":["Verubecestat 12 mg (Parts 1 and 2)","Verubecestat 40 mg (Parts 1 and 2)","Placebo (Part 1)"],"nct_id":"NCT01953601","overall_status":"TERMINATED","phases":["PHASE3"],"primary_outcomes":["Part 1 (Base Study). Least Squares Mean (LSM) Change From Baseline in Clinical Dementia Rating Sum of Boxes (CDR-SB) Score at Week 104","Part 2 (Extension Study). Mean Change From Baseline in Clinical Dementia Rating Sum of Boxes (CDR-SB) Score at Week 130","Part 1 (Base Study). Percentage of Participants Who Experienced ≥1 Adverse Event (AE)","Part 1 (Base Study). Percentage of Participants Who Discontinued From Study Drug Due to an Adverse Event (AE)","Part 2 (Extension Study). Percentage of Participants Who Experienced ≥1 Adverse Event (AE)","Part 2 (Extension Study). Percentage of Participants Who Discontinued From Study Drug Due to an Adverse Event (AE)"],"retrieved_at":"2026-05-06T03:57:55.915650+00:00","source_api":"clinicaltrials.gov-v2","start_date":"2013-11-05"},"name":"Efficacy and Safety Trial of Verubecestat (MK-8931) in Participants With Prodromal Alzheimer's Disease (MK-8931-019)","provenance":{"authors":[],"citation_count":null,"doi":null,"extraction":{"extracted_at":"2026-05-06T03:57:55.915666+00:00","extractor_version":"0.54.0","method":"artifact_deposit","model":null,"model_version":null},"journal":null,"license":"ClinicalTrials.gov public record","openalex_id":null,"pmc":null,"pmid":null,"review":null,"source_type":"clinical_trial","title":"Efficacy and Safety Trial of Verubecestat (MK-8931) in Participants With Prodromal Alzheimer's Disease (MK-8931-019)","url":"https://clinicaltrials.gov/study/NCT01953601","year":null},"retracted":false,"size_bytes":283956,"source_url":"https://clinicaltrials.gov/study/NCT01953601","storage_mode":"local_blob","target_findings":["vf_247ab84f7a601b89"]},"proposal_id":"vpr_b8a5c75fbaeb92ed"},"reason":"public trial record for anti-amyloid frontier (NCT01953601)","schema":"vela.event.v0.1","signature":"1a6cab8b2fb1e0be1799486161d80dbb3f8186ad1a993d3a08d8c908d0bb15613f7eb70a9aaa7427ef5aa489639db576489877dc72426b0aa8dfabe6985bb909","target":{"id":"va_4f9a1656fdcd89fb","type":"artifact"},"timestamp":"2026-05-06T03:57:55.929497+00:00"}],"log_total":303,"next_cursor":"vev_50412918baab20e8","schema":"vela.events-page.v0.1","vfr_id":"vfr_5076e7b3ff8e6b0f"}